<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Commun</journal-id><journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id><journal-id journal-id-type="pmc-domain-id">2873</journal-id><journal-id journal-id-type="pmc-domain">ncomms</journal-id><journal-title-group><journal-title>Nature Communications</journal-title></journal-title-group><issn pub-type="epub">2041-1723</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12141615</article-id><article-id pub-id-type="pmcid-ver">PMC12141615.1</article-id><article-id pub-id-type="pmcaid">12141615</article-id><article-id pub-id-type="pmcaiid">12141615</article-id><article-id pub-id-type="pmid">40473640</article-id><article-id pub-id-type="doi">10.1038/s41467-025-60570-2</article-id><article-id pub-id-type="publisher-id">60570</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Bacterial membrane nanovesicles encapsulating prodrug assemblies combine chemical and immunological therapies for chronic bacterial infection</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0002-9139-3139</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="Y">Yuanfeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>He</surname><given-names initials="W">Wei</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Piao</surname><given-names initials="Y">Yinzi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yumeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peng</surname><given-names initials="M">Mengna</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="H">Huaping</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hu</surname><given-names initials="R">Rongdang</given-names></name><address><email>hurongdang@hotmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="D">Dongdong</given-names></name><address><email>ldd@ucas.ac.cn</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="L">Linqi</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1738-7857</contrib-id><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yong</given-names></name><address><email>y.liu@nankai.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03cyvdv85</institution-id><institution-id institution-id-type="GRID">grid.414906.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0918</institution-id><institution>Translational Medicine Laboratory, </institution><institution>The First Affiliated Hospital of Wenzhou Medical University, </institution></institution-wrap>Wenzhou, Zhejiang China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rd5t069</institution-id><institution-id institution-id-type="GRID">grid.268099.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0348 3990</institution-id><institution>Department of Orthodontics School and Hospital of Stomatology, </institution><institution>Wenzhou Medical University Wenzhou, </institution></institution-wrap>Wenzhou, Zhejiang China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qbk4x57</institution-id><institution-id institution-id-type="GRID">grid.410726.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 8419</institution-id><institution>Wenzhou Institute, </institution><institution>University of Chinese Academy of Sciences, </institution></institution-wrap>Wenzhou, Zhejiang China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01y1kjr75</institution-id><institution-id institution-id-type="GRID">grid.216938.7</institution-id><institution-id institution-id-type="ISNI">0000 0000 9878 7032</institution-id><institution>State Key Laboratory of Medicinal Chemical Biology, </institution><institution>Nankai University, </institution></institution-wrap>Tianjin, China </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478256</issue-id><elocation-id>5246</elocation-id><history><date date-type="received"><day>16</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>06</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-07 00:25:19.647"><day>07</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41467_2025_Article_60570.pdf"/><abstract id="Abs1"><p id="Par1">Overcoming challenges in drug targeting and modulating the immunosuppressive microenvironment are critical for treating chronic bacterial infections, which are often characterized by intracellular bacteria and biofilms. To overcome these barriers, we report a multifunctional nanomedicine (C<italic toggle="yes">p</italic>E@BMV). The prodrug conjugate (C<italic toggle="yes">p</italic>E), composed of two phenylboronic acid-modified ciprofloxacin (Cip-<italic toggle="yes">pba</italic>) molecules and ellagic acid (Ea), self-assembles due to its hydrophobic nature and &#960;&#8211;&#960; stacking. Bacterial membrane vesicles (BMVs) derived from <italic toggle="yes">Escherichia coli</italic> aid in C<italic toggle="yes">p</italic>E assembly and structural stabilization. Upon administration, pathogen-associated molecular patterns on C<italic toggle="yes">p</italic>E@BMV engage toll-like receptors on macrophages, activating these cells and enhancing their phagocytic response. Once internalized, C<italic toggle="yes">p</italic>E responds to elevated intracellular H&#8322;O&#8322; levels, releasing Cip to eliminate intracellular bacteria. Additionally, Ea scavenges excess reactive oxygen species in inflamed macrophages and modulates the expression of inflammatory factors, preventing an exaggerated inflammatory response. The C<italic toggle="yes">p</italic>E@BMV formulation also penetrates biofilms, eliminating bacteria and releasing antigens. These antigens are transported to draining lymph nodes, where they induce dendritic cell maturation and trigger a robust T and B cell-mediated immune response, helping restore immune balance and combat pathogens effectively in female mouse models. Therefore, our C<italic toggle="yes">p</italic>E@BMV provide an efficient strategy combining chemical and immunological therapies for chronic bacterial infection management.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">Effective delivery of therapeutic agents to the infection site and the modulation of the immunosuppressive microenvironment at the site of infection are vital for the treatment of chronic bacterial infections but remain elusive. Here, the authors address these issues by developing a nanomedicine that combines chemical and immunological therapies for chronic bacterial infection management.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Drug delivery</kwd><kwd>Bacterial infection</kwd><kwd>Biomedical materials</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution></institution-wrap></funding-source><award-id>52422307</award-id><award-id>22275043</award-id><award-id>52203184</award-id><award-id>52293383</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Yuanfeng</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Linqi</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Yong</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004731</institution-id><institution>Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation)</institution></institution-wrap></funding-source><award-id>LR24H180001</award-id><principal-award-recipient><name name-style="western"><surname>Liu</surname><given-names>Yong</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">Chronic bacterial infections pose a substantial challenge in healthcare, primarily due to the persistence of intracellular bacteria and the formation of resilient bacterial biofilms<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Intracellular bacteria, capable of residing within host cells, evade immune surveillance and antimicrobial treatments, leading to persistent infections that are difficult to eradicate<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. These intracellular pathogens exploit host cells as a niche for replication, avoiding direct exposure to the immune system&#8217;s defenses and some antimicrobial treatments<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. In addition, bacterial biofilms further exacerbate the complexity of chronic infections by providing a protective environment for bacteria to thrive<sup><xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref></sup>. Biofilms are structured communities encased in a self-produced extracellular matrix, shielding bacteria from host immune responses and rendering them highly resistant to antibiotics<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. The formation of biofilms not only enhances bacterial survival but also contributes to the chronicity and recurrent nature of infections<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Therefore, in the treatment of chronic bacterial infections, two major challenges arise: the first being the delivery of therapeutic agents to overcome barriers and reach the site of infection, and the second involving the modulation of the immunosuppressive microenvironment at the site of infection.</p><p id="Par4">Overcoming delivery barriers entails leveraging strategies such as employing nanocarriers, liposomes, or nanoparticles to bolster drug penetration and retention at the infection site, surmount biofilm obstacles, and enhance intracellular drug delivery for targeting persistent bacteria<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. Addressing the immunosuppressive microenvironment necessitates the development of immunomodulatory therapies<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, including immune checkpoint inhibitors, cytokine treatments, or immunostimulatory agents, to revive immune function, amplify immune responses, and facilitate bacterial clearance. While immunomodulatory therapies have become a cornerstone of cancer treatment, their application to chronic bacterial infections presents unique challenges, particularly when modulating adaptive immunity<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. One of the key hurdles is the limited immunogenicity of bacterial antigens within the biofilm matrix, which impairs antigen presentation and subsequent T cell activation<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Additionally, the immunosuppressive milieu is characterized by diminished antigen-presenting cell efficacy, impaired T cell function, reduced B cell somatic hypermutation, and attenuated antibody responses<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. Chronic infections also lead to the aberrant activation of immune-suppressive cells, such as regulatory T cells (Tregs), which further complicates the immune response against biofilm-associated bacteria<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Moreover, the disrupted balance of co-inhibitory and co-stimulatory signals within adaptive immune pathways undermines the effectiveness of antibody-based therapies targeting the bacteria. Given these challenges, we propose that dual strategies&#8212;aiming to optimize drug delivery and enhance immune responses&#8212;hold promise for effectively combating chronic bacterial infections<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>.</p><p id="Par5">Bacteria-derived membrane vesicles (BMVs) hold significant promise for cargo delivery and immunomodulatory therapy. These naturally occurring MVs exhibit a remarkable ability to transport virulence factors, toxins, and pathogen-associated molecular patterns (PAMPs) from the parent bacterium to host cells, thereby triggering a cascade of inflammatory and immunomodulatory responses<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. The notable features of MVs include their stability, non-replicative nature, and the diverse array of PAMPs inherent to the parent bacterium, thus positioning them as compelling candidates for vaccine development<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. MVs have demonstrated remarkable efficacy in delivering genetically engineered peptides or proteins derived from the parent bacterium, exemplified by the presence of autolysin murein hydrolase in Pseudomonas vesicles<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> or specific antigens in <italic toggle="yes">Escherichia coli</italic> (<italic toggle="yes">E. coli</italic>) outer membrane vesicles<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Despite their advantageous properties, the robust structure of bacteria-derived MVs presents a challenge in effectively delivering chemotherapeutic agents, impeding the optimal penetration and diffusion of pharmaceutical compounds.</p><p id="Par6">In this study, we have developed a prodrug conjugation strategy for antibiotics that can autonomously assemble in the presence of bacterial membranes, resulting in the creation of a multifunctional nanomedicine (C<italic toggle="yes">p</italic>E@BMV) designed for the treatment of chronic bacterial infections. We hypothesize that the prodrug conjugation (C<italic toggle="yes">p</italic>E), formed by combining two phenylboronic acid (<italic toggle="yes">pba</italic>)-modified ciprofloxacin (Cip) (Cip-<italic toggle="yes">pba</italic>) molecules with one ellagic acid (Ea), can self-assemble owing to its hydrophobic properties (Fig.&#160;<xref rid="Fig1" ref-type="fig">1a</xref>). Bacterial membranes sourced from <italic toggle="yes">E. coli</italic> were utilized to facilitate the assembly of C<italic toggle="yes">p</italic>E and stabilize the resultant structures. Upon administration, the PAMPs on the surface of BMVs can engage with toll-like receptors on macrophages, activating these immune cells and augmenting their phagocytic activity against the infecting bacteria (Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>). Furthermore, once internalized by macrophages, the encapsulated C<italic toggle="yes">p</italic>E can respond to elevated intracellular H<sub>2</sub>O<sub>2</sub> levels, leading to the release of Cip to eradicate intracellular bacteria. Additionally, Ea can scavenge excess reactive oxygen species (ROS) within inflamed macrophages and downregulate the pro-inflammatory factors, thereby preventing an exaggerated inflammatory response, such as an inflammatory storm, that could harm normal tissues. Moreover, our C<italic toggle="yes">p</italic>E@BMV formulation exhibits the ability to penetrate bacterial biofilms and eliminate the bacteria residing within, releasing bacterial antigens in the process. Subsequently, these generated antigens are transported to draining lymph nodes. Within lymph nodes, the maturation of dendritic cells (DCs) is induced by antigens, enabling them to efficiently present to T cells and initiating T and B cells -mediated immune response. This coordinated immune response serves to maintain immune homeostasis and effectively combat external pathogens.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Schematic diagram illustrating the preparation of C<italic toggle="yes">p</italic>E@BMV and the proposed mechanism of action to enhance antimicrobial immune response.</title><p><bold>a</bold> Preparation of C<italic toggle="yes">p</italic>E@BMV via BMV cloaked prodrug C<italic toggle="yes">p</italic>E. BMV was extracted from <italic toggle="yes">E. coli</italic>. Prodrug C<italic toggle="yes">p</italic>E was synthesized using Cip and Ea with a <italic toggle="yes">pba</italic> linker. <bold>b</bold> C<italic toggle="yes">p</italic>E@BMV facilitated bacterial killing and immune regulator. 1#: <italic toggle="yes">E. coli</italic> was killed by C<italic toggle="yes">p</italic>E@BMV, resulting in the release of PAMPs that combined with BMV to induce macrophage polarization; 2#: M0 macrophage polarized into M1-like macrophage for efficient phagocytosis of <italic toggle="yes">E. coli</italic>; 3#: uptakes of C<italic toggle="yes">p</italic>E@BMV nanoparticles led to Ea release, further reprogramming M1-like to M2-like macrophage; 4#: generated PAMPs was delivered into immature DC; 5#: promoted DC maturation; 6#: na&#239;ve T cells were activated and differentiated into specific CD8<sup>+</sup> T cells for eliminated <italic toggle="yes">E.coli</italic>; 7#: activated na&#239;ve T cells differentiated into CD4<sup>+</sup> T cells; 8#: B cells was activated by CD4<sup>+</sup> T cells and contributed to the elimination of <italic toggle="yes">E. coli</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e505" position="float" orientation="portrait" xlink:href="41467_2025_60570_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>BMV stabilizes C<italic toggle="yes">p</italic>E</title><p id="Par7">The prodrug molecule, C<italic toggle="yes">p</italic>E, was synthesized by utilizing dynamic boronate bonds between ellagic acid (Ea) and boronic acid-modified ciprofloxacin (Cip-<italic toggle="yes">pba</italic>) in dimethyl sulfoxide at a molar ratio of EA: Cip-<italic toggle="yes">pba</italic> of 1:2. Cip-<italic toggle="yes">pba</italic> was prepared following our established procedure through the reaction of Cip with 4-bromophenylboronic acid (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">1</xref>)<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>. After the reaction, the chemical shift at 28.44&#8201;ppm of Cip-<italic toggle="yes">pba</italic> disappeared in their corresponding <sup>11</sup>B NMR spectra. Conversely, the appearance of a new peak at 8.78&#8201;ppm indicated the formation of a boronate ester (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2a</xref>), consistent with our previous observations<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Furthermore, mass spectrometry showed characteristic peaks at 1161.43 and 1183.42, confirming the formation of C<italic toggle="yes">p</italic>E (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2b</xref>). Further, <sup>1</sup>H&#8211;<sup>1</sup>H COSY and NOSY spectra illustrated that the protons on Ea and Cip are coupled, suggesting that Ea and Cip are adjacent (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2c, d</xref>). In the infrared spectrum, a sharp absorption peak near 3478&#8201;cm<sup>&#8211;1</sup> (O&#8211;H stretching of Ea) disappeared post-reaction, while C<italic toggle="yes">p</italic>E retained the B-OC absorption peak around 1015&#8201;cm<sup>&#8211;1</sup> (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">3a</xref>). The UV-vis spectrum of C<italic toggle="yes">p</italic>E showed an absorption peak at 273&#8201;nm, indicating the presence of Cip-<italic toggle="yes">pba</italic> (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">3b</xref>). These results collectively suggest the successful preparation of the C<italic toggle="yes">p</italic>E molecule.</p><p id="Par8">Concurrently, BMV was extracted from <italic toggle="yes">E. coli</italic> DH5&#945;, one of the most common laboratory strains, using a chemical lysis method with a yield of 29%. The isolated BMV exhibited an amorphous structure (Fig.&#160;<xref rid="Fig2" ref-type="fig">2a</xref>). Notably, when dispersing Cip+Ea (physical mixture) and C<italic toggle="yes">p</italic>E in phosphate buffer (PB, pH 7.4, 10&#8201;mM), rapid precipitation occurred, resulting in aggregates with sizes exceeding 1000&#8201;nm (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">3c</xref>). This phenomenon is likely attributed to the high hydrophobicity of C<italic toggle="yes">p</italic>E, with a calculated LogP (partition coefficient) (ClogP) of approximately 3.7 (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">1b</xref>). A higher cLogP value indicates increased hydrophobicity of a substance. Interestingly, when C<italic toggle="yes">p</italic>E was dispersed in the BMV suspension and subjected to extrusion, a stable new suspension was produced, with a diameter of around 100&#8201;nm with narrow distribution and negatively charged surfaces (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">3c, d</xref>). This observation aligns with our previous publication, which demonstrated that the cell membrane can stabilize the prodrug conjugate<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Transmission electron microscopy (TEM) imaging revealed the formation of a core-shell structure in the BMV-stabilized C<italic toggle="yes">p</italic>E (referred to as C<italic toggle="yes">p</italic>E@BMV thereafter). The thickness of the shell was determined to be around 10&#8201;nm, consistent with the BMV thickness<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, indicating that BMV contributes to the formation and stability of C<italic toggle="yes">p</italic>E in an aqueous environment. As a proof-of-concept, the size of C<italic toggle="yes">p</italic>E@BMV exhibited minimal variations during a 7-day observation period at room temperature, while the size of C<italic toggle="yes">p</italic>E aggregates gradually increased to up to 2000&#8201;nm under the same storage conditions (Fig.&#160;<xref rid="Fig2" ref-type="fig">2b</xref>). Further elemental mapping images of C<italic toggle="yes">p</italic>E@BMV (Fig.&#160;<xref rid="Fig2" ref-type="fig">2c, d</xref>) indicated the distribution of phosphorus (P) elements on the surface of BMV, while boron (B) and fluorine (F) elements are solely distributed within the interior. Furthermore, Dil-labeled BMV was used to encapsulate Cy5-labeled C<italic toggle="yes">p</italic>E, followed by analysis using flow cytometry. The percentage of Dil+/Cy5+ assemblies reached 85.8% (Fig.&#160;<xref rid="Fig2" ref-type="fig">2e</xref>), indicating co-localization of BMV and C<italic toggle="yes">p</italic>E in the C<italic toggle="yes">p</italic>E@BMV.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Characterization of C<italic toggle="yes">p</italic>E@BMV.</title><p><bold>a</bold> Representative TEM images of C<italic toggle="yes">p</italic>E, BMV, and C<italic toggle="yes">p</italic>E@BMV. Scale bar: 100&#8201;nm. For C<italic toggle="yes">p</italic>E@BMV, the thickness of the BMV film in C<italic toggle="yes">p</italic>E@BMV was around 20&#8201;nm. <bold>b</bold> Colloidal diameter of Cip+Ea, C<italic toggle="yes">p</italic>E, and C<italic toggle="yes">p</italic>E@BMV in phosphate buffer (PB, pH 7.4, 10&#8201;mM) over a 7-day period was measured using DLS. The C<italic toggle="yes">p</italic>E and C<italic toggle="yes">p</italic>E@BMV were diluted to a final concentration of 0.1&#8201;mg/mL for size measurement. Data are presented as mean&#8201;&#177;&#8201;s.d. (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent samples). <bold>c</bold> Elemental mapping image of C<italic toggle="yes">p</italic>E@BMV showing the distribution of P, F, and B elements. <bold>d</bold> Gray value distribution along the arrow in (<bold>c</bold>) for P, F, and B elements in C<italic toggle="yes">p</italic>E@BMV. <bold>e</bold> Representative nano-flow cytometry analysis of C<italic toggle="yes">p</italic>E@BMV. BMV and prodrug C<italic toggle="yes">p</italic>E core were labeled with Dil (yellow) and Cy5 (red), respectively. <bold>f</bold> Snapshots from the all-atom simulations illustrate the assembly process of C<italic toggle="yes">p</italic>E without BMV at different time points, with an enlargement showing the planar structure of Ea and the stacking of Ea driving aggregate formation. <bold>g</bold> Snapshots from the all-atom simulations depict the assembly process of C<italic toggle="yes">p</italic>E in the presence of BMV at different time points. The insertion of C<italic toggle="yes">p</italic>E into the bacterial membrane is indicated by the red arrows. The upper leaflet, middle leaflet, and lower leaflet of the bacterial outer membrane vesicles are represented in purple, green, and orange, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e747" position="float" orientation="portrait" xlink:href="41467_2025_60570_Fig2_HTML.jpg"/></fig></p><p id="Par9">To further explore the self-assembly behavior of C<italic toggle="yes">p</italic>E in the presence or absence of BMV, all-atom simulations were conducted. In the absence of BMV, the planar structure of Ea facilitates the parallel stacking of C<italic toggle="yes">p</italic>E molecules through &#960;-&#960; interactions (Fig.&#160;<xref rid="Fig2" ref-type="fig">2f</xref>, Supplementary Movie&#160;<xref rid="MOESM4" ref-type="media">1</xref>), resulting in the formation of numerous small aggregates within 50&#8201;ns and a larger irregular structure at 100&#8201;ns. These larger aggregates demonstrate a lack of long-range order, assembling randomly to create disordered aggregates, consistent with our experimental observations.</p><p id="Par10">Conversely, in the presence of BMV, within the initial 10&#8201;ns, most C<italic toggle="yes">p</italic>E molecules coalesce similarly to their behavior in the absence of BMV, owing to their hydrophobic properties. Subsequently, after 10&#8201;ns, some small C<italic toggle="yes">p</italic>E aggregates began to associate with BMV. By 25&#8201;ns, as the C<italic toggle="yes">p</italic>E aggregate diffused and came into contact with the outer membrane surface, it was attracted to the exposed regions of the C<italic toggle="yes">p</italic>E molecules embedded in the membrane, thereby becoming anchored to the membrane surface. Over time, the entire aggregate gradually adhered to the membrane surface, culminating in the formation of a stable binding configuration by the conclusion of the 100&#8201;ns simulation (Fig.&#160;<xref rid="Fig2" ref-type="fig">2g</xref>, Supplementary Movie&#160;<xref rid="MOESM5" ref-type="media">2</xref>). These in-silico findings once again underscore the significant role of BMV in the self-assembly process and stability.</p><p id="Par11">Analysis of the protein composition in C<italic toggle="yes">p</italic>E@BMV via sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) revealed that most membrane proteins from BMV were retained in C<italic toggle="yes">p</italic>E@BMV (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">3e</xref>). At physiological pH (pH 7.4), the release of Cip from C<italic toggle="yes">p</italic>E@BMV was relatively slow, with only 15% release efficiency achieved after 48&#8201;h. However, exposure to a microenvironment with pH 6.5 and the presence of hydrogen peroxide significantly accelerated Cip release from C<italic toggle="yes">p</italic>E@BMV, achieving 70% release efficiency (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">4a</xref>). Further size measurements confirmed the stability of C<italic toggle="yes">p</italic>E@BMV at pH 7.4. In contrast, their size increased to approximately 2&#8201;&#956;m when exposed to pH 6.5 and hydrogen peroxide conditions (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">4b</xref>), possibly due to the triggering of the cleavage of <italic toggle="yes">pba</italic> and release of free Cip when C<italic toggle="yes">p</italic>E@BMV are exposed to hydrogen peroxide.</p><p id="Par12">To determine if antimicrobial agent binding and BMV encapsulation affect the antimicrobial efficacy of the composed antimicrobial agents, <italic toggle="yes">Staphylococcus aureus</italic> WH<sup>GFP</sup> (<italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup>), <italic toggle="yes">E. coli</italic> Xen14, <italic toggle="yes">Salmonella Typhimurium</italic> 15,649 (<italic toggle="yes">S. Typhimurium</italic> 15,649) were treated with Cip, C<italic toggle="yes">p</italic>E, and C<italic toggle="yes">p</italic>E@BMV in solution to determine their minimum inhibitory concentration and bactericidal concentration (MIC and MBC) against these two multidrug-resistant bacteria. Cip and C<italic toggle="yes">p</italic>E demonstrated the same concentration MIC and MBC values, while C<italic toggle="yes">p</italic>E@BMV demonstrated a 4-fold lower MIC and a 2-fold lower MBC (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">1</xref>). Similar results were observed with live/dead staining, where C<italic toggle="yes">p</italic>E@BMV demonstrated significantly higher bactericidal efficacy compared to other treatments (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">5a</xref>). Therefore, it can be conservatively concluded that either conjugation or membrane encapsulation does not have a negative impact on antimicrobial efficacy.</p></sec><sec id="Sec4"><title>Immune-stimulatory C<italic toggle="yes">p</italic>E@BMV boosts the immune responses of RAW264.7 macrophages</title><p id="Par13">Macrophages are essential for effective innate and adaptive immune responses against bacterial infections. To assess whether the changes in immune suppression and co-stimulatory molecules induced by C<italic toggle="yes">p</italic>E@BMV stimulate subsequent immune responses, the polarization state and phagocytic ability of RAW264.7 macrophages were analyzed. Flow cytometry analysis showed a significant increase in the percentage of M1-phenotype macrophages in the C<italic toggle="yes">p</italic>E@BMV group, indicating successful activation of M0 macrophages into M1 pro-inflammatory macrophages (Fig.&#160;<xref rid="Fig3" ref-type="fig">3a</xref>). Further studies demonstrated that RAW264.7 macrophages treated with C<italic toggle="yes">p</italic>E@BMV exhibited a higher bacterial phagocytosis rate compared to other treatments (Fig.&#160;<xref rid="Fig3" ref-type="fig">3b</xref>). Additionally, to further confirm whether C<italic toggle="yes">p</italic>E@BMV was successfully taken up by infected macrophages, infected RAW264.7 macrophages were co-incubated with C<italic toggle="yes">p</italic>E and C<italic toggle="yes">p</italic>E@BMV for 2&#8201;h. Compared to bare C<italic toggle="yes">p</italic>E, C<italic toggle="yes">p</italic>E@BMV is more readily internalized by activated macrophages. This is because the presence of BMV facilitates its uptake by macrophages, which in turn internalize the encapsulated C<italic toggle="yes">p</italic>E. Confocal laser scanning microscopy (CLSM) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3c</xref>) and Flow cytometry (Fig.&#160;<xref rid="Fig3" ref-type="fig">3d</xref>) confirmed the successful internalization of C<italic toggle="yes">p</italic>E@BMV by infected macrophages. Importantly, C<italic toggle="yes">p</italic>E@BMV taken up by infected macrophages released Cip under acidic and hydrogen peroxide conditions, aiding in the clearance of bacteria within macrophages. This was validated by a significant decrease in the green fluorescence intensity of <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> in the CLSM images of the macrophages receiving the treatment of C<italic toggle="yes">p</italic>E@BMV (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">5b</xref>). Quantitative analysis of the green fluorescence intensity of <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> within macrophages in each group supported this conclusion (Fig.&#160;<xref rid="Fig3" ref-type="fig">3e</xref>). Next, to demonstrate the bactericidal effect of C<italic toggle="yes">p</italic>E@BMV on extracellular and intracellular <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> and <italic toggle="yes">E. coli</italic> Xen14, bacteria were mixed with C<italic toggle="yes">p</italic>E@BMV at a Cip concentration of 0.44&#8201;&#956;g/mL. At the same concentration, the marginal inhibitory difference in extracellular bacteria was observed after the treatments of Cip-<italic toggle="yes">pba</italic>, C<italic toggle="yes">p</italic>E, and C<italic toggle="yes">p</italic>E@BMV (Fig.&#160;<xref rid="Fig3" ref-type="fig">3f</xref>). However, C<italic toggle="yes">p</italic>E@BMV was significantly more efficient in eradicating intercellular bacteria, especially in a shorter period of exposure time (Fig.&#160;<xref rid="Fig3" ref-type="fig">3f, g</xref>, Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">6a</xref>). In addition, similar results were observed with <italic toggle="yes">S. Typhimurium</italic> 15,649, a clinical isolate and typical intracellular pathogen, where our C<italic toggle="yes">p</italic>E@BMVs were significantly more effective in eradicating intracellular bacteria compared to all other treatments (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">6b</xref>). These findings highlight the exceptional bactericidal efficacy of C<italic toggle="yes">p</italic>E@BMVs in eliminating intracellular bacteria.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>C<italic toggle="yes">p</italic>E@BMV infiltrated macrophages and stimulated them for intracellular bacterial eradication.</title><p><bold>a</bold> Flow cytometry analysis illustrating the changes in CD86 (M1 marker) and CD206 (M2 marker) expression in RAW264.7 macrophages following different treatments and statistical analysis of the ratio of M1/M2 macrophages, equivalent to CD86-positive/CD206-positive cells. <bold>b</bold> Representative flow cytometry image and quantitative analysis of the phagocytosis of <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> by RAW264.7 macrophages treated as specified. <bold>c</bold> Representative CLSM image depicting RAW264.7 cells with intracellular <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> (white arrow) post-treatment with Nile Red-labeled C<italic toggle="yes">p</italic>E and C<italic toggle="yes">p</italic>E@BMV (red arrow). Each experiment was repeated three times independently with similar results. <bold>d</bold> Flow cytometry analysis of fluorescence intensity in the infected RAW264.7 macrophages after co-incubation with Nile Red-labeled C<italic toggle="yes">p</italic>E and C<italic toggle="yes">p</italic>E@BMV for 2&#8201;h. <bold>e</bold> Quantitative analysis of green fluorescence intensity of <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> (live bacteria) within macrophages following treatment with PBS, C<italic toggle="yes">p</italic>E, and C<italic toggle="yes">p</italic>E@BMV. <bold>f</bold>, <bold>g</bold> Statistical analysis of the c.f.u. of extracellular (<bold>f</bold>) and intracellular (<bold>g</bold>) surviving <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> in cocultures of bacteria and RAW264.7 macrophages after exposure to different treatments for 12, 24, and 48&#8201;h. Data are mean&#8201;&#177;&#8201;s.d. of <italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent samples. Statistical significance was determined by one-way ANOVA with Tukey&#8217;s multiple comparisons test, <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05, no significance (<italic toggle="yes">ns</italic>), *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; and ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001. Source data are provided as a Source Data file.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1086" position="float" orientation="portrait" xlink:href="41467_2025_60570_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>ROS scavenging and anti-inflammatory activity of C<italic toggle="yes">p</italic>E@BMV</title><p id="Par14">To study the ROS scavenging ability of C<italic toggle="yes">p</italic>E@BMV, representative ROS and reactive nitrogen species, namely H<sub>2</sub>O<sub>2</sub> (hydrogen peroxide), &#8226;OH (hydroxyl radical), and &#8226;O<sub>2</sub><sup>&#8722;</sup> (superoxide anion radical), ABTS<sup>+</sup> (2,2&#8242;-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)), and DPPH (2,2-diphenyl-1-picrylhydrazyl) were used. They are generated by enzymatic catalysis reactions, Fenton reactions, xanthine and xanthine oxidase reactions, where &#8226;OH and &#8226;O<sub>2</sub><sup>&#8722;</sup> are reactive oxygen species that can cause DNA damage, lipid peroxidation, and protein breakage. Over 60% of H<sub>2</sub>O<sub>2</sub> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4a</xref>), over 85% of &#8226;OH (Fig.&#160;<xref rid="Fig4" ref-type="fig">4b</xref>), and over 90% of &#8226;O<sub>2</sub><sup>&#8722;</sup> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4c</xref>) were eliminated by C<italic toggle="yes">p</italic>E@BMV with a concentration over 125&#8201;&#181;g/mL. Furthermore, the excellent ROS scavenging ability of C<italic toggle="yes">p</italic>E@BMV was further confirmed through classical ABTS<sup>+</sup> and DPPH radical scavenging assays (Fig.&#160;<xref rid="Fig4" ref-type="fig">4d, e</xref>). The multiple antioxidant properties of C<italic toggle="yes">p</italic>E are likely attributed to the presence of <italic toggle="yes">pba</italic> and Ea in C<italic toggle="yes">p</italic>E<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. It is important to note that the concentrations used here were approximately 10-fold higher than those typically found in vivo, to meet the sensitivity requirements of the assay kit. Despite this, even the lowest nanoparticle concentration (3.9&#8201;&#956;g/mL of Cip) effectively scavenged 20%&#8211;60% of the high levels of ROS, demonstrating the strong ROS scavenging capacity of C<italic toggle="yes">p</italic>E@BMVs.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>C<italic toggle="yes">p</italic>E@BMV scavenges the excessive ROS of LPS-induced macrophages.</title><p><bold>a</bold>&#8211;<bold>e</bold> ROS scavenging efficiency of C<italic toggle="yes">p</italic>E@BMV toward H<sub>2</sub>O<sub>2</sub> (<bold>a</bold>), &#8226;OH (<bold>b</bold>), &#8226;O<sub>2</sub><sup>&#8211;</sup> (<bold>c</bold>), ABTS+ (<bold>d</bold>), and DPPH (<bold>e</bold>) at different nanoparticles concentrations (<italic toggle="yes">n</italic>&#8201;=&#8201;3 independent samples). <bold>f</bold> Fluorescence images of intracellular ROS in LPS-treated RAW264.7 cells after various treatments. RAW264.7 cells were stained with a DCFH-DA fluorescence probe. Scale bar: 20&#8201;&#956;m. <bold>g</bold>&#8211;<bold>j</bold> The levels of TNF-&#945; (<bold>g</bold>), IL-6 (<bold>h</bold>), IL-1&#946; (<bold>i</bold>), and IL-10 (<bold>j</bold>) in the supernatant of RAW264.7 macrophages after different treatments for 24&#8201;h were examined using ELISAs. Data are presented as means&#8201;&#177;&#8201;s.d. (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent samples). Statistical significance was determined using one-way ANOVA with Tukey&#8217;s post hoc test, <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05, no significance (<italic toggle="yes">ns</italic>), *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; and ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1248" position="float" orientation="portrait" xlink:href="41467_2025_60570_Fig4_HTML.jpg"/></fig></p><p id="Par15">Further investigation was conducted to determine if C<italic toggle="yes">p</italic>E@BMV could eliminate intracellular ROS and protect against ROS-mediated damage. Moreover, to simulate an environment with high ROS expression in vitro, macrophages (RAW264.7) were pretreated with lipopolysaccharide (LPS) to induce inflammation and excessive ROS production. As shown in Fig.&#160;<xref rid="Fig4" ref-type="fig">4f</xref>, under LPS stimulation, cells produced an excess of ROS under oxidative stress conditions, evidenced by a significant increase in strong green fluorescence signal via dichlorofluorescein (DCF). However, treatment with C<italic toggle="yes">p</italic>E@BMV significantly reduced the green fluorescence signal, and the cell viability was significantly increased (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">7</xref>), validating the cell-protective ability of C<italic toggle="yes">p</italic>E@BMV against ROS-mediated damage. In addition to mitigating intracellular ROS overexpression, C<italic toggle="yes">p</italic>E@BMV effectively downregulated pro-inflammatory cytokine production. The anti-inflammatory potential of C<italic toggle="yes">p</italic>E@BMV was further evaluated, showing significant reductions in pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-&#945;), interleukin-6 (IL-6), and interleukin-1&#946; (IL-1&#946;), compared to other treatments. Conversely, the anti-inflammatory cytokine IL-10 was upregulated following C<italic toggle="yes">p</italic>E@BMV treatment (Fig.&#160;<xref rid="Fig4" ref-type="fig">4g&#8211;j</xref>). As anticipated, C<italic toggle="yes">p</italic>E@BMV reduced all major pro-inflammatory cytokines, highlighting its broad anti-inflammatory activity. These findings suggest that C<italic toggle="yes">p</italic>E@BMV possesses strong ROS scavenging capabilities and notable anti-inflammatory properties.</p></sec><sec id="Sec6"><title>C<italic toggle="yes">p</italic>E@BMV eliminates <italic toggle="yes">E. coli</italic> biofilms</title><p id="Par16">Next, biofilm elimination was evaluated in the presence of Cip, C<italic toggle="yes">p</italic>E, and C<italic toggle="yes">p</italic>E@BMV. The results showed that only a minimal amount of <italic toggle="yes">E. coli</italic> biofilm was dispersed following treatment with free Cip or C<italic toggle="yes">p</italic>E, indicating a lack of significant biofilm dispersal capability. This finding was further corroborated by the corresponding CLSM images, which revealed minimal disruption of the biofilm structure in both treatments (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">8a</xref>). In contrast, under the same conditions, C<italic toggle="yes">p</italic>E@BMV effectively eradicated the mature <italic toggle="yes">E. coli</italic> biofilms. Subsequent quantitative data showed that the green fluorescence intensity of biofilms treated with C<italic toggle="yes">p</italic>E@BMV was significantly lower than those treated with free Cip or C<italic toggle="yes">p</italic>E (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">8b</xref>). Detection of biomass, thickness, and roughness of biofilms treated with various agents revealed that the biomass and thickness of biofilms after treatment with C<italic toggle="yes">p</italic>E@BMV were significantly lower than those treated with free Cip or C<italic toggle="yes">p</italic>E (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">8c, d</xref>), with higher roughness compared to biofilms treated with free Cip or C<italic toggle="yes">p</italic>E (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">8e</xref>). Similar results were observed in crystal violet-stained biofilms, where the total biofilm volume of biofilms treated with C<italic toggle="yes">p</italic>E@BMV was significantly lower than those treated with free Cip or C<italic toggle="yes">p</italic>E (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">7f</xref>). Additionally, colony-forming unit (c.f.u.) enumeration of bacteria embedded in biofilms after various treatments was counted. Biofilms treated with C<italic toggle="yes">p</italic>E@BMV showed significantly fewer viable bacteria compared to those treated with Cip or C<italic toggle="yes">p</italic>E (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">8g</xref>). These results collectively demonstrate that our C<italic toggle="yes">p</italic>E@BMV can effectively eliminate <italic toggle="yes">E. coli</italic> biofilm formation. Of note, BMVs induce biofilm formation by delivering signaling molecules and adhesion factors that promote bacterial aggregation and surface attachment, while also facilitating the production of extracellular matrix components<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. In our study, the effect of BMVs on biofilm formation was minimal, likely due to the short 4-h incubation, which did not allow sufficient time for the BMVs to exert their effects.</p></sec><sec id="Sec7"><title>C<italic toggle="yes">p</italic>E@BMV eliminates bacteria and inflammation in a pneumonia model</title><p id="Par17">Furthermore, an animal model of mouse pneumonia was established using <italic toggle="yes">E. coli</italic> Xen14 to further evaluate the antimicrobial action of C<italic toggle="yes">p</italic>E@BMV. The pneumonia model was constructed using the reported method<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, and infected mice were treated with various therapies via tracheal intubation on days 1, 2, 3, and 6 (Fig.&#160;<xref rid="Fig5" ref-type="fig">5a</xref>). On the 7th day, all infected mice were sacrificed, and lung tissues were homogenized for c.f.u. enumeration. Compared to the PBS-treated group, treatment with C<italic toggle="yes">p</italic>E@BMV resulted in a reduction of c.f.u. by over 4&#8201;log units (Fig.&#160;<xref rid="Fig5" ref-type="fig">5b</xref>). Compared to free Cip, C<italic toggle="yes">p</italic>E@BMV induced a more pronounced reduction in c.f.u. (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001). Additionally, histological assessment using Hematoxylin and Eosin (H&amp;E) staining of lung tissue sections was conducted to evaluate the extent of tissue necrosis. As shown in Fig.&#160;<xref rid="Fig5" ref-type="fig">5c</xref>, lung alveoli in healthy, uninfected lungs were intact and hollow. In contrast, lung alveoli fusion and incomplete inflation were observed in the PBS group, indicating severe bacterial infection. In comparison, the C<italic toggle="yes">p</italic>E@BMV-treated group maintained relatively healthy lung tissue, suggesting successful eradication of the bacterial infection. Furthermore, an immune profiling analysis of the infected draining lymph nodes (IDLN) and lung tissues demonstrated that C<italic toggle="yes">p</italic>E@BMV activated various immune cells in the pneumonia model. Treatment with C<italic toggle="yes">p</italic>E@BMV significantly reduced the proportion of pro-inflammatory M1-like macrophages (F4/80<sup>+</sup>CD86<sup>+</sup>) and increased the proportion of anti-inflammatory M2-like macrophages (F4/80<sup>+</sup>CD206<sup>+</sup>) in the lungs on days 3 and 7 post-treatment (Fig.&#160;<xref rid="Fig5" ref-type="fig">5d, e</xref>, Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">9</xref>). Immunofluorescence staining was used to determine the phenotypes of macrophages after various treatments. Immunofluorescence imaging (Fig.&#160;<xref rid="Fig5" ref-type="fig">5f</xref>) revealed a significant presence of F4/80<sup>+</sup>CD86<sup>+</sup> macrophages in the lung tissues of the PBS-treated mice, indicating macrophage activation and transition to the pro-inflammatory M1 phenotype. In contrast, C<italic toggle="yes">p</italic>E@BMV reduced the levels of F4/80<sup>+</sup>CD86<sup>+</sup> macrophages and increased the levels of F4/80<sup>+</sup>CD206<sup>+</sup> macrophages. Further flow cytometry indicated that the C<italic toggle="yes">p</italic>E@BMV treatment notably increases the expression of mature dendritic cells (CD11c<sup>+</sup>CD80<sup>+</sup>CD86<sup>+</sup>), facilitates CD8<sup>+</sup> T cells (CD3<sup>+</sup>CD8<sup>+</sup>), CD4<sup>+</sup> T cells (CD3<sup>+</sup>CD4<sup>+</sup>), infiltrated T cells (CD4<sup>+</sup>Foxp3<sup>+</sup>) activation and proliferation, increases the numbers of plasma cells (CD138<sup>+</sup>CD19<sup>+</sup>) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5g&#8211;k</xref>, Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">9</xref>). Importantly, mice treated with C<italic toggle="yes">p</italic>E@BMV exhibited a significant reduction in pro-inflammatory cytokines such as TNF-&#945;, IL-1&#946;, and IL-6, and a significant increase in the anti-inflammatory cytokine interleukin-10 (IL-10) in the infected tissue and serum (Fig.&#160;<xref rid="Fig5" ref-type="fig">5l&#8211;o</xref>, Supplementary Figs.&#160;<xref rid="MOESM1" ref-type="media">10</xref>&#8211;<xref rid="MOESM1" ref-type="media">12</xref>). These results further demonstrate that the ability of C<italic toggle="yes">p</italic>E@BMV to enhance immune cell infiltration in lung tissues, eliciting a robust antibacterial immune response in the case of bacterial infection. Therefore, our C<italic toggle="yes">p</italic>E@BMV can prevent inflammation caused by bacterial infections and effectively eradicate bacteria, while exhibiting minimal cytotoxicity towards model cells and normal tissues (Supplementary Figs.&#160;<xref rid="MOESM1" ref-type="media">13</xref>&#8211;<xref rid="MOESM1" ref-type="media">15</xref>). In the context of multidrug-resistant bacterial infections, antibody responses are considered a key protective factor for neutralizing bacteria. Furthermore, we observed an increase in pro-inflammatory M1-like macrophage expression after BMV treatment, reflecting the activation of immune cells in vivo. This data confirms that BMVs, rather than C<italic toggle="yes">p</italic>E, play a crucial role in triggering antibacterial immune responses.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>C<italic toggle="yes">p</italic>E@BMV effectively suppresses <italic toggle="yes">E. coli</italic> pulmonary infection in vivo.</title><p><bold>a</bold> Experimental scheme of the <italic toggle="yes">E. coli</italic>-induced pulmonary infection model in female BALB/c mice. Different formulations administered via tracheal needle on days 1, 2, 3, and 6 using equivalent doses of Cip, Ea, and BMV were 1.76&#8201;mg/kg, 0.76&#8201;mg/kg, and 1.12&#8201;mg/kg, respectively (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent mice). <bold>b</bold> Quantified c.f.u. of <italic toggle="yes">E. coli</italic> in excised lung tissues from treatment endpoints was performed (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent mice). <bold>c</bold> Representative H&amp;E staining images of the collected lung tissues from different groups after various treatments on day 7. Each experiment was repeated three times independently with similar results. <bold>d</bold>, <bold>e</bold> Representative scatter plots of flow cytometry data and quantitative results demonstrated the percentage of M1-phenotype macrophages (<bold>d</bold>) and M2-phenotype macrophages (<bold>e</bold>) within the CD11b<sup>+</sup>F4/80<sup>+</sup> cell population in the lung tissues on day 7 after various treatments (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent mice). <bold>f</bold> Representative immunofluorescent images were captured for lung tissues. Each experiment was repeated three times independently with similar results. <bold>g</bold>&#8211;<bold>k</bold> Representative scatter plots of flow cytometry data and quantitative results showing the number of mature DCs (CD80<sup>+</sup>CD86<sup>+</sup>) (<bold>g</bold>), CD8<sup>+</sup> T cells (CD3<sup>+</sup>CD8<sup>+</sup>) (<bold>h</bold>), CD4<sup>+</sup> T cells (CD3<sup>+</sup>CD4<sup>+</sup>) (<bold>i</bold>), regulatory T cells (CD3<sup>+</sup>CD4<sup>+</sup>Foxp3<sup>+</sup>) (<bold>j</bold>), plasmablasts (CD138<sup>+</sup>CD19<sup>+</sup>) and plasma cells (CD138<sup>+</sup>CD19<sup>&#8722;</sup>) (<bold>k</bold>) (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent mice). <bold>l</bold>&#8211;<bold>o</bold> Cytokine concentrations of TNF-&#945; (<bold>l</bold>), IL-6 (<bold>m</bold>), IL-1&#946; (<bold>n</bold>), and IL-10 (<bold>o</bold>) in the infected lung tissue from the mice that received various treatments as measured by ELISA (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent mice). Data are presented as means&#8201;&#177;&#8201;s.d. Statistical significance was determined using one-way ANOVA with Tukey&#8217;s post hoc test, <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05, no significance (<italic toggle="yes">ns</italic>), *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; and ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1678" position="float" orientation="portrait" xlink:href="41467_2025_60570_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec8"><title>Mechanisms of C<italic toggle="yes">p</italic>E@BMV in the treatment of bacterial pneumonia in vivo</title><p id="Par18">To analyze the underlying mechanisms of C<italic toggle="yes">p</italic>E@BMV in the treatment of bacterial pneumonia, an RNA-seq of lung tissue was conducted. Lung tissue samples from BALB/c mice after 3 days and 7 days of treatment with PBS, Cip, or C<italic toggle="yes">p</italic>E@BMV were collected and analyzed. A total of 392 differentially expressed genes (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 &amp; |log<sub>2</sub>FC&#8201;|&#8201;&gt;&#8201;1.0) were identified between the PBS-treated and C<italic toggle="yes">p</italic>E@BMV-treated mice, after 3 days and 7 days of treatment, respectively (Fig.&#160;<xref rid="Fig6" ref-type="fig">6a</xref>, Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">16a</xref>). A cluster heatmap was generated to visualize the expression of some differentially expressed genes in the two groups (Fig.&#160;<xref rid="Fig6" ref-type="fig">6b</xref>, Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">16b</xref>). In the C<italic toggle="yes">p</italic>E@BMV-treated mice, some genes related to anti-inflammation and tissue repair were expressed higher compared to the PBS-treated group both after 3 days and 7 days of treatment, such as <italic toggle="yes">Dusp1</italic>, which helps maintain mitochondrial function and structural integrity after tissue injury<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>, and <italic toggle="yes">Fasl</italic>, which is related to immune privilege to protect the tissue site<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> (Fig.&#160;<xref rid="Fig6" ref-type="fig">6b</xref>, Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">16b</xref>). Conversely, genes related to tissue damage and inflammatory response were overexpressed in PBS-treated mice, including <italic toggle="yes">Wnt7b</italic>, which is related to abnormally activated <italic toggle="yes">Wnt</italic> signaling in lung tissue and severe pulmonary epithelial injury<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, <italic toggle="yes">Tnf</italic>, which is strongly related to cell death and chronic inflammation<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, and <italic toggle="yes">Saa3</italic>, which stimulates pro-inflammatory cytokine expression<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> (Fig.&#160;<xref rid="Fig6" ref-type="fig">6b</xref>). Gene ontology (GO) network analysis revealed that, compared to the PBS-treated group, pathways involved in adaptive immune response and anti-inflammatory pathways were upregulated in the C<italic toggle="yes">p</italic>E@BMV-treated group, both after 3 days and 7 days of treatment. This included the enhanced T cell proliferation and T cell-mediated cytotoxicity, an enhanced adaptive immune response, and the negative regulation of the inflammatory signaling pathway <italic toggle="yes">p38MAPK</italic>, which produces interleukin-1 and tumor-necrosis factor<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> (Fig.&#160;<xref rid="Fig6" ref-type="fig">6c</xref>), as well as T cell-mediated immunity and B cell activation after 3 days treatment (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">16c</xref>). Meanwhile, some GO terms related to pro-inflammation were downregulated in the C<italic toggle="yes">p</italic>E@BMV-treated group both after 3 days and 7 days of treatment, including the positive regulation of type II interferon production, cellular response to interleukin-1, and negative regulation of interleukin-10 production<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> (Fig.&#160;<xref rid="Fig6" ref-type="fig">6d</xref>), as well as tumor necrosis factor binding after 3 days treatment (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">16d</xref>). Gene set enrichment analysis (GSEA) revealed that integration of energy metabolism had higher activity in C<italic toggle="yes">p</italic>E@BMV-treated group compared to the C<italic toggle="yes">p</italic>E@BMV-treated group after 3 days treatment (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">16e</xref>). The <italic toggle="yes">PPAR</italic> signaling pathway and cellular response to <italic toggle="yes">VEGF</italic> in the PBS-treated group showed lower activity compared to the C<italic toggle="yes">p</italic>E@BMV-treated group (Fig.&#160;<xref rid="Fig6" ref-type="fig">6e, f</xref>). The <italic toggle="yes">PPAR</italic> signaling pathway controls cellular metabolism and exerts anti-inflammatory effects on immune cells<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. The cellular response to <italic toggle="yes">VEGF</italic> is a key signaling pathway mediating physiological angiogenesis, crucial for tissue repair<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. The lower expression of <italic toggle="yes">PPAR</italic> and the cellular response to <italic toggle="yes">VEGF</italic> in the PBS-treated group indicates that the lung tissue failed to transition from the inflammatory phase to the lung repair phase, whereas the C<italic toggle="yes">p</italic>E@BMV-treated group showed greater success in anti-inflammation and infected lung tissue repair (Fig.&#160;<xref rid="Fig6" ref-type="fig">6e, f</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><title>Transcriptome sequencing and microbiota analysis in the pulmonary model on day 7 post various treatments.</title><p><bold>a</bold> Volcano plot displayed the distributions of upregulated and downregulated genes (&#8805;2-fold difference, <italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05) in the C<italic toggle="yes">p</italic>E@BMV grou<italic toggle="yes">p</italic> compared to the PBS group. None, non-differentially expressed genes (DEGs). <bold>b</bold> Heatmaps of different groups of upregulated and downregulated DEGs related to immune response pathways. <bold>c</bold>, <bold>d</bold> Gene ontology (GO) enrichment analysis of DEGs performed for both upregulated (<bold>c</bold>) and downregulated (<bold>d</bold>) GO terms between the C<italic toggle="yes">p</italic>E@BMV-treated mice and PBS-treated mice. <bold>e</bold>, <bold>f</bold> Gene set enrichment analysis (GSEA) of DEGs enriched in PPAR signaling pathway (<bold>e</bold>) and cellular response to VEGF stimulus (<bold>f</bold>). <bold>g</bold> Relative abundance of the top 7 family-level taxa in the lung microbiome across healthy mice, PBS, Cip, and C<italic toggle="yes">p</italic>E@BMV treatments. <bold>h</bold> Relative abundance of various taxa in the healthy mice, PBS, Cip, and C<italic toggle="yes">p</italic>E@BMV treatments. Red, pathogenic strains in lung infection. Green, non-pathogenic strains. <bold>i</bold> Predicted functional compositions of the microbial communities in the healthy mice, PBS, Cip, and C<italic toggle="yes">p</italic>E@BMV treatments. Data are presented as means&#8201;&#177;&#8201;s.d. Statistical significance was determined using one-way ANOVA with Tukey&#8217;s post hoc test, <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05, no significance (<italic toggle="yes">ns</italic>), *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; and ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1939" position="float" orientation="portrait" xlink:href="41467_2025_60570_Fig6_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>C<italic toggle="yes">p</italic>E@BMV reshapes the lung microbiome after infection in vivo</title><p id="Par19">In pneumonia, a large number of bacteria invade the lung tissue, resulting in dysbiosis of the mouse lung microbiome. To reveal changes in the lung microbiome, a 2bRAD sequencing for microbiome (2bRAD-M) was conducted. Compared to ribosomal 16s RNA sequencing, 2bRAD-M offers higher accuracy and sensitivity, generating species-level taxonomic profiles and enabling qualitative and relative quantitative analysis of microbes, providing information on most bacterial species. Lung tissue samples from BALB/c mice after 3 days and 7 days of treatment with PBS, Cip, or C<italic toggle="yes">p</italic>E@BMV were collected and analyzed. The relative abundance of different taxa at the family-level changed significantly after infection, especially with an increase in the abundance of <italic toggle="yes">Enterobacteriaceae</italic> and a decrease in <italic toggle="yes">Burkholderiaceae</italic> (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">16f</xref>). Meanwhile, the C<italic toggle="yes">p</italic>E@BMV-treated mice showed a lower abundance of <italic toggle="yes">Enterobacteriaceae</italic> and a higher abundance of <italic toggle="yes">Burkholderiaceae</italic> after 3 days of treatment, compared to PBS and Cip-treated mice, indicating a faster recover of microbiome (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">16f</xref>). After 7 days treatment, the community abundance in the PBS-treated mice is still quite different from that in healthy mice, Cip-treated and C<italic toggle="yes">p</italic>E@BMV-treated mice. The top three abundant families in PBS-treated mice are <italic toggle="yes">Neisseriaceae</italic> (12%), <italic toggle="yes">Enterobacteriaceae</italic> (10%), and <italic toggle="yes">Porphyromonadaceae</italic> (8%), indicating that pathogenic <italic toggle="yes">E. coli</italic> remains the major bacterium after PBS treatment. The top three families in healthy mice, Cip-treated mice, and C<italic toggle="yes">p</italic>E@BMV-treated mice are the same: <italic toggle="yes">Burkholderiaceae</italic> (52% in healthy mice, 42% in Cip-treated mice, and 45% in C<italic toggle="yes">p</italic>E@BMV-treated mice), <italic toggle="yes">Rikenellaceae</italic> (18% in healthy mice, 14% in Cip-treated mice, and 29% in C<italic toggle="yes">p</italic>E@BMV-treated mice), and <italic toggle="yes">Sphingomonadaceae</italic> (11% in healthy mice, 12% in Cip-treated mice, and 8% in C<italic toggle="yes">p</italic>E@BMV-treated mice), none of these families belong to pathogenic bacteria. (Fig.&#160;<xref rid="Fig6" ref-type="fig">6g</xref>). Subsequently, the relative abundance of species between different groups was displayed using a heatmap (Fig.&#160;<xref rid="Fig6" ref-type="fig">6h</xref>, Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">16g</xref>). The species abundance in the PBS group differs significantly from the healthy group, while Cip and C<italic toggle="yes">p</italic>E@BMV effectively restore the abundance of some pathogenic strains to normal levels, including the reduced considerably abundance of <italic toggle="yes">Enterobacteriaceae</italic>, <italic toggle="yes">Neisseriaceae</italic>and <italic toggle="yes">Porphyromonadaceae</italic>, and maintained non-pathogenic <italic toggle="yes">Burkholderiaceae, Sphingomonadaceae</italic>, and <italic toggle="yes">Lachnospiracesa</italic>in at a higher level (Fig.&#160;<xref rid="Fig6" ref-type="fig">6h</xref>, Supplementary Figs.&#160;<xref rid="MOESM1" ref-type="media">16g</xref> and <xref rid="MOESM1" ref-type="media">17a</xref>). There are also significant differences in microbial metabolism and bacterial functional changes after C<italic toggle="yes">p</italic>E@BMV treatment. We used Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2) to predict the functional composition of the microbial communities in different groups (Fig.&#160;<xref rid="Fig6" ref-type="fig">6i</xref>). The results show that the mean proportion of ribosome-binding factor A, folypolyglutamates synthase/dihydropteroate synthase, and glucose-6-phosphate isomerase in the PBS-treated and Cip-treated mice were significantly lower than those in the C<italic toggle="yes">p</italic>E@BMV-treated and healthy mice, indicating that mitochondrial ribosome biogenesis, protein synthesis, and glycolysis in the lung microbiome are less active (Fig.&#160;<xref rid="Fig6" ref-type="fig">6i</xref>, Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">17b</xref>). This situation was significantly improved in the C<italic toggle="yes">p</italic>E@BMV-treated mice, as evidenced by the similar proportions between healthy mice and C<italic toggle="yes">p</italic>E@BMV-treated mice (Fig.&#160;<xref rid="Fig6" ref-type="fig">6i</xref>). These results indicate that the C<italic toggle="yes">p</italic>E@BMV treatment can reshape the lung microbiome after infection and help it recover to a healthy level.</p></sec><sec id="Sec10"><title>C<italic toggle="yes">p</italic>E@BMV responds to recurrent peritonitis by enhancing long-term immunity</title><p id="Par20">To study the efficacy of C<italic toggle="yes">p</italic>E@BMV to treat the widespread peritonitis in vivo, we used <italic toggle="yes">E. coli</italic> Xen14 to establish a peritonitis animal model. Two hours post-infection, mice were treated with various formulations, and all measurements were taken during a 24-h observation period (Fig.&#160;<xref rid="Fig7" ref-type="fig">7a</xref>). During the 24-h observation period, a decreasing trend in bioluminescence intensity at the infection site was observed in mice treated with free Cip, but notably, C<italic toggle="yes">p</italic>E@BMV treatment resulted in a significant and rapid decrease in bioluminescence intensity at the infection site (Fig.&#160;<xref rid="Fig7" ref-type="fig">7b</xref>). Quantitative analysis of bioluminescence intensity showed that over 85% of the bioluminescence intensity decreased within the first 8&#8201;h after treatment with C<italic toggle="yes">p</italic>E@BMV, indicating rapid bacterial killing and prevention of further bacterial infection development (Fig.&#160;<xref rid="Fig7" ref-type="fig">7c</xref>). The bacterial counts of <italic toggle="yes">E. coli</italic> per gram of homogenized organ tissues from five organs were quantified, revealing that the C<italic toggle="yes">p</italic>E@BMV treatment exhibited a significant reduction (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) in c.f.u. compared to the Cip treatment, particularly showing significant bactericidal effects in the heart, liver, and kidneys (Fig.&#160;<xref rid="Fig7" ref-type="fig">7d1&#8211;d5</xref>). For bacteria in ascites, both free Cip and C<italic toggle="yes">p</italic>E@BMV demonstrated considerable clearance efficiency. While free Cip exhibited notable extracellular bactericidal performance, its intracellular inhibition of <italic toggle="yes">E. coli</italic> was quite low. In contrast, C<italic toggle="yes">p</italic>E@BMV effectively killed intracellular <italic toggle="yes">E. coli</italic> and demonstrated optimal therapeutic efficacy (Fig.&#160;<xref rid="Fig7" ref-type="fig">7d6</xref>).<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><title>C<italic toggle="yes">p</italic>E@BMV exhibits bacterial eradication activity in the peritonitis model and established immunological memory in vivo.</title><p><bold>a</bold> Experimental scheme of the <italic toggle="yes">E. coli</italic> peritonitis model in female BALB/c mice. Different formulations administered via i.p. on day 1 using equivalent doses of Cip, Ea, and BMV were 1.76&#8201;mg/kg, 0.76&#8201;mg/kg, and 1.12&#8201;mg/kg, respectively (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent mice). <bold>b</bold> Bioluminescent images of the mice with peritonitis model after various treatments. <bold>c</bold> Quantified bioluminescence intensity from the images in (<bold>b</bold>) (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent mice). <bold>d</bold><sub><bold>1</bold></sub>&#8211;<bold>d</bold><sub><bold>6</bold></sub> Quantitative analysis of survival <italic toggle="yes">E. coli</italic> in <bold>d</bold><sub>1</sub> heart, <bold>d</bold><sub>2</sub> liver, <bold>d</bold><sub>3</sub> spleen, <bold>d</bold><sub>4</sub> lung, <bold>d</bold><sub>5</sub> kidney, and <bold>d</bold><sub>6</sub> ascites fluid of the mice receiving various treatments on day 2 (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent mice). <bold>e</bold>&#8211;<bold>k</bold> Representative scatter plots of flow cytometry data and quantitative results showing the number of M1-phenotype macrophages (F4/80<sup>+</sup>CD80<sup>+</sup>) (<bold>e</bold>), M2-phenotype macrophages (F4/80<sup>+</sup>CD206<sup>+</sup>) (<bold>f</bold>), mature DCs (CD80<sup>+</sup>CD86<sup>+</sup>) (<bold>g</bold>), CD8<sup>+</sup> and CD4<sup>+</sup> T cells (<bold>h</bold>), regulatory T cells (CD3<sup>+</sup>CD4<sup>+</sup>Foxp3<sup>+</sup>) (<bold>i</bold>), plasmablasts (CD138<sup>+</sup>CD19<sup>+</sup>) (<bold>j</bold>), and memory B cells (CD19<sup>+</sup>CD38<sup>&#8722;</sup>) (<bold>k</bold>) (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent mice). <bold>l</bold>&#8211;<bold>o</bold> Cytokine concentrations of TNF-&#945; (<bold>l</bold>), IL-6 (<bold>m</bold>), IL-1&#946; (<bold>n</bold>), and IL-10 (<bold>o</bold>) in the peritoneal fluid from the mice that received various treatments as measured by ELISA (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent mice). Data are presented as means&#8201;&#177;&#8201;s.d. Statistical significance was determined using one-way ANOVA with Tukey&#8217;s post hoc test, <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05, no significance (<italic toggle="yes">ns</italic>), *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; and ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2317" position="float" orientation="portrait" xlink:href="41467_2025_60570_Fig7_HTML.jpg"/></fig></p><p id="Par21">Encouraged by the high efficacy of C<italic toggle="yes">p</italic>E@BMV to inhibit bacterial proliferation, we further evaluated the ability of C<italic toggle="yes">p</italic>E@BMV for long-term immune memory in vivo, providing enduring protective immunity against reinfection with Gram-negative bacteria. In addition to the initial peritoneal infection and C<italic toggle="yes">p</italic>E@BMV treatment, the immune mice were infected and treated post-infection on days 7 and 14, followed by immune cell analysis of macrophages, DC cells, B cells, and T cells in the spleen after sacrificing the mice on days 3 and 15. Similar to the immune response in the pneumonia infection model, a decrease in the expression levels of M1-like macrophages (F4/80<sup>+</sup>CD86<sup>+</sup>) and an increase in the expression levels of M2-like macrophages (F4/80<sup>+</sup>CD206<sup>+</sup>) were observed in the C<italic toggle="yes">p</italic>E@BMV treatment group, along with higher levels of mature DCs (CD11c<sup>+</sup>CD80<sup>+</sup>CD86<sup>+</sup>), CD8<sup>+</sup> T cells (CD3<sup>+</sup>CD8<sup>+</sup>), CD4<sup>+</sup> helper T cells (CD3<sup>+</sup>CD4<sup>+</sup>), and plasma cells (CD19<sup>+</sup>CD138<sup>+</sup>) infiltration (Fig.&#160;<xref rid="Fig7" ref-type="fig">7e&#8211;j</xref>, Supplementary Figs.&#160;<xref rid="MOESM1" ref-type="media">18</xref> and <xref rid="MOESM1" ref-type="media">19</xref>). To evaluate the level of pathogen-specific immune memory stimulation, memory B cells (CD45<sup>+</sup>CD19<sup>+</sup>CD38<sup>&#8211;</sup>) significantly increased in mice compared to untreated mice (Fig.&#160;<xref rid="Fig7" ref-type="fig">7k</xref>). To study the inflammatory response in mice receiving various treatments, pro-inflammatory cytokines IL-1&#946;, IL-6, and TNF-&#945;, and anti-inflammatory cytokine IL-10 in ascites fluid and serum were measured. In ascites fluid, treatment with C<italic toggle="yes">p</italic>E@BMV significantly neutralized pro-inflammatory cytokines, outperforming other treatments. Furthermore, treatment with C<italic toggle="yes">p</italic>E@BMV significantly promoted the expression of IL-10 in ascites fluid (Fig.&#160;<xref rid="Fig7" ref-type="fig">7l&#8211;o</xref>) and the serum (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">20</xref>). These results collectively demonstrate that C<italic toggle="yes">p</italic>E@BMV can effectively eradicate bacteria in the peritonitis model, alleviate inflammation, and help prevent reinfection while enhancing the body&#8217;s resistance by activating memory B cells.</p><p id="Par22">Moreover, the pharmacokinetic/pharmacodynamic (PK/PD) parameters were analyzed to evaluate the efficacy of C<italic toggle="yes">p</italic>E@BMV in comparison to free Cip. PK/PD parameters describe the relationship between drug exposure and bacterial killing, aiding in the optimization of antibiotic dosing strategies to achieve maximal therapeutic effects while minimizing the risk of resistance development<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Based on the blood Cip concentration, we observed that C<italic toggle="yes">p</italic>E@BMV significantly prolonged the bioavailability of Cip, with its 24-h AUC being 8.2 times higher than that of free Cip (Fig.&#160;<xref rid="Fig8" ref-type="fig">8a, b</xref>, and Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">21</xref>). This substantial increase suggests that the nanoparticle-based delivery system enhances systemic circulation time and drug retention, potentially leading to improved clinical outcomes.<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><title>C<italic toggle="yes">p</italic>E@BMV enhances the pharmacokinetic profile of Cip.</title><p><bold>a</bold> Cip concentration in plasma following peritoneal infection with either Cip or C<italic toggle="yes">p</italic>E@BMV at different time intervals. Data are presented as mean&#8201;&#177;&#8201;S.D. (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biological replicates). <bold>b</bold> Area under the curve calculated from (<bold>a</bold>). <bold>c</bold> Heatmap showing the Peak/MIC ratio of Cip and C<italic toggle="yes">p</italic>E@BMV against the various pathogens. <bold>d</bold> Heatmap showing the 24-h AUC/MIC ratio of Cip and C<italic toggle="yes">p</italic>E@BMV against the various pathogens.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2458" position="float" orientation="portrait" xlink:href="41467_2025_60570_Fig8_HTML.jpg"/></fig></p><p id="Par23">Peak/MIC (Cmax/MIC) represents the ratio of the maximum drug concentration to the MIC, which is crucial for concentration-dependent antibiotics like Cip, where bacterial killing efficacy increases with higher peak concentrations. The recommended target for Peak/MIC is &#8805;8&#8211;10 to ensure optimal antimicrobial activity<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. In our study, the Peak/MIC ratio of free Cip ranged from 13 to 26, already exceeding the minimum threshold. However, C<italic toggle="yes">p</italic>E@BMV further elevated the Peak/MIC ratio to a range of 22&#8211;44 (Fig.&#160;<xref rid="Fig8" ref-type="fig">8c</xref>), indicating a greater potential for rapid bacterial eradication. The significantly higher Peak/MIC of C<italic toggle="yes">p</italic>E@BMV suggests improved drug delivery efficiency and greater potential for achieving therapeutic success, particularly in severe infections requiring high peak concentrations for bacterial eradication.</p><p id="Par24">24-h AUC/MIC (AUC24/MIC) reflects total drug exposure over 24&#8201;h relative to MIC and is particularly important for time-dependent or exposure-dependent antibiotics like Cip. Recommended AUC24/MIC targets for fluoroquinolones are &#8805;125 for Gram-negative bacteria and &#8805;30&#8211;50 for Gram-positive bacteria, ensuring sufficient drug exposure to suppress bacterial growth and prevent resistance selection. In our study, the AUC24/MIC of free Cip ranged from 19 to 39, which is below the required threshold, particularly for Gram-negative pathogens. This suboptimal exposure may contribute to inadequate bacterial clearance and a higher likelihood of resistance development over time. In contrast, C<italic toggle="yes">p</italic>E@BMV exhibited an AUC24/MIC range of 319&#8211;638 (Fig.&#160;<xref rid="Fig8" ref-type="fig">8d</xref>), far exceeding the necessary levels. This remarkable improvement underscores the enhanced drug retention and sustained release profile of C<italic toggle="yes">p</italic>E@BMV, which may lead to prolonged bacterial suppression and reduced dosing frequency, thereby improving patient compliance and treatment efficacy.</p><p id="Par25">These findings highlight the superior pharmacokinetic performance of C<italic toggle="yes">p</italic>E@BMV compared to free Cip, emphasizing its potential to improve treatment outcomes in bacterial infections. The significant enhancements in both Peak/MIC and AUC24/MIC suggest that C<italic toggle="yes">p</italic>E@BMV could offer more effective bacterial eradication, prolonged therapeutic coverage, and a reduced risk of resistance development<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Further investigations, including in vivo efficacy studies and clinical trials, are warranted to confirm these advantages and assess the long-term benefits of this drug delivery system.</p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p id="Par26">Prodrug assemblies amalgamate the benefits of prodrugs and nanomedicines<sup><xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref></sup>. Typically, prodrug assemblies exhibit high drug loading capacities and mitigate premature drug release and potential drug-related side effects. In this study, we employed Ea bearing two catechol domains to engage in a reaction with Cip-<italic toggle="yes">pba</italic>, resulting in the formation of the C<italic toggle="yes">p</italic>E prodrug through dynamic covalent boronate bonding. A notable advantage of this dynamic covalent bonding process is the generation of two water molecules without the involvement of harmful organic solvents, thus averting the potential side effects stemming from residual organic solvent remnants<sup><xref ref-type="bibr" rid="CR46">46</xref>&#8211;<xref ref-type="bibr" rid="CR48">48</xref></sup>. Moreover, the C<italic toggle="yes">p</italic>E prodrug showcases a significantly high drug loading content (&gt;95%), surpassing the drug loading contents typically observed in conventional drug delivery systems, which usually fall below 10%. This underscores the paramount significance of our C<italic toggle="yes">p</italic>E prodrug, which is facilitated by dynamic covalent bonding.</p><p id="Par27">Another notable advantage of our C<italic toggle="yes">p</italic>E prodrug, which incorporates Cip and Ea, lies in its potential to surmount bacterial drug resistance and inflammation by leveraging a combination of antibiotics and their adjuvants. Cip typically functions by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, crucial for bacterial DNA replication, transcription, repair, and recombination processes. Conversely, polyphenols often target bacterial cell membranes. By concurrently targeting distinct bacterial elements, the likelihood of bacteria developing drug resistance is diminished, and in certain cases, existing drug resistance may even be reversed<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. While the amalgamation of drugs holds significant promise in combating bacterial drug resistance, the dissimilar pharmacological characteristics of individual drugs can impede their efficacy in reaching their intended targets spontaneously. Our C<italic toggle="yes">p</italic>E prodrug, which combines two distinct drugs, presents an efficacious strategy for the spontaneous delivery of drugs, thereby enhancing therapeutic outcomes.</p><p id="Par28">Moreover, the presence of Ea in the C<italic toggle="yes">p</italic>E formulation enhances its self-assembly, facilitated by the planar structure of Ea and the strong &#960;&#8211;&#960; stacking interactions. It is worth noting that the irregular structure of Cip at the terminals of C<italic toggle="yes">p</italic>E leads to the self-assembled structures of C<italic toggle="yes">p</italic>E exhibiting a disordered arrangement, prone to forming amorphous structures and aggregates. To enhance the stability of C<italic toggle="yes">p</italic>E self-assemblies, we introduced the BMV. Our all-atom simulation findings indicate that BMV effectively mitigates the excessive aggregation of C<italic toggle="yes">p</italic>E, with the Cip domain of C<italic toggle="yes">p</italic>E potentially embedding into the membrane and acting as an anchoring point. Consequently, the spherical configuration of BMV acts as a confinement for C<italic toggle="yes">p</italic>E assemblies, thereby stabilizing the resulting suspensions. Remarkably, we have observed that our C<italic toggle="yes">p</italic>E aggregates adhere to the inner surface of the BMV, which is distinguished by a reduced presence of lipopolysaccharides. This phenomenon may be attributed to the enhanced interactions between C<italic toggle="yes">p</italic>E and lipids, surpassing those with lipopolysaccharides. Moreover, the nanoparticulate nature of C<italic toggle="yes">p</italic>E@BMV also facilitates the penetration of drugs into bacterial biofilms, as has been extensively observed in numerous previous studies<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR51">51</xref></sup>, ultimately enhancing the efficacy of bacterial eradication in their biofilm growth mode.</p><p id="Par29">An alternative effective strategy in addressing antimicrobial resistance involves the utilization of vaccines. Bacteria-derived membrane vesicles containing a plethora of PAMPs have the ability to trigger innate immune signaling pathways and have been harnessed as vaccine adjuvants and carriers in cancer therapy<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Gram-negative bacteria utilize two primary mechanisms for vesicle formation: outer membrane blebbing and explosive cell lysis. In contrast, Gram-positive bacteria undergo a process called &#8220;bubbling cell death,&#8221; triggered by endolysin, which leads to the formation of cytoplasmic membrane vesicles<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Since BMVs derived from Gram-negative bacteria are easier to prepare and more commonly used, we employed BMVs from <italic toggle="yes">E. coli</italic> in our study as a model system to encapsulate the prodrug conjugate and stimulate the immune response. These BMV exhibit remarkable stability, are non-pathogenic, and can be genetically engineered nanoparticles housing crucial immunogenic proteins from the originating bacterium<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup>. They have the capacity to induce immune responses from both the innate and adaptive immune systems, making them well-suited for roles as vaccine candidates and immune modulators<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. The chemical lysis method and bacterial cell wall disruption were used instead of traditional OMV isolation methods because they provide a higher yield and are more efficient in breaking open bacterial cells. This approach is faster, cost-effective, and allows for better control over the release of cellular contents. Traditional OMV isolation methods, like ultracentrifugation, can be more time-consuming and may not always yield consistent or pure results<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. The higher yield of our BMV (29%) compared with the commonly used outer membrane vesicles<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> for vaccine (&lt;0.01%)<sup><xref ref-type="bibr" rid="CR57">57</xref></sup> is a big advantage for broader application. Antigen-presenting cells (APCs) play a crucial role in bacterial infection, as the occurrence of infection significantly affects the activity and function of APCs, impacting immune responses and regulation<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. The transformation of APCs suggests that C<italic toggle="yes">p</italic>E@BMV promotes the processing and presentation of bacterial antigens. The significant increase in the expression of mature dendritic cells (CD11c<sup>+</sup>CD80<sup>+</sup>CD86<sup>+</sup>) facilitates T cell activation and proliferation. The increase in CD8<sup>+</sup> T cells (CD3<sup>+</sup>CD8<sup>+</sup>) infiltration indicates the essential role of cytotoxic T cells in immune regulation, involved in clearing infected and abnormal cells, participating in immune responses, maintaining immune homeostasis, and protecting the body from pathogens and abnormal cells. Additionally, an increase in CD4<sup>+</sup> T cells (CD3<sup>+</sup>CD4<sup>+</sup>) infiltration further suggests that C<italic toggle="yes">p</italic>E@BMV enhances humoral immune responses, regulates inflammatory responses, and maintains the normal function of the immune system<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. Furthermore, a sharp decrease in infiltrated T cells (CD4<sup>+</sup>Foxp3<sup>+</sup>) indicates that C<italic toggle="yes">p</italic>E@BMV restricts the migration of T cells to the immune microenvironment, leading to a reduction in immune suppression and increased immune response activity. B cells, as specialized APCs, differentiate into plasma cells and memory B cells upon infection, participating in humoral immune responses by producing antibodies to neutralize and eliminate invading bacteria, thereby protecting the body from infection<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. An increase in plasma cells (CD138<sup>+</sup>CD19<sup>+</sup>) in the immune microenvironment following treatment with C<italic toggle="yes">p</italic>E@BMV suggests that C<italic toggle="yes">p</italic>E@BMV induces antigen-specific humoral immune responses, enhancing humoral immune efficacy and enabling mice to produce a large quantity of antibodies more rapidly and effectively upon encountering the same bacteria again, leading to a faster and stronger immune response<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>.</p><p id="Par30">Bacterial pneumonia arises when host defenses are compromised and/or when the host is exposed to highly virulent or a significant number of microorganisms. Additionally, prior infections and chronic lung conditions can contribute to the development of pneumonia<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. The process of the host immune system clearing pathogen infections and further repairing lung tissue typically involves two sequential phases: the pro-inflammatory phase and the anti-inflammatory phase. During the pro-inflammatory phase, pathogen eradication is promoted through enhanced phagocytic activity and ROS generation, while the subsequent anti-inflammatory phase aids in tissue repair and remodeling<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. Transcriptomic data analysis of lung tissue collected after 7 days of treatment demonstrated that the C<italic toggle="yes">p</italic>E@BMV-treated mice exhibited downregulated pro-inflammatory genes and signaling pathways (Fig.&#160;<xref rid="Fig6" ref-type="fig">6b&#8211;e</xref>), consistent with measurements of inflammatory cytokines (Fig.&#160;<xref rid="Fig5" ref-type="fig">5l&#8211;o</xref>). Concurrently, the pathogen quantity significantly decreased in the C<italic toggle="yes">p</italic>E@BMV-treated group (Fig.&#160;<xref rid="Fig5" ref-type="fig">5b</xref>). These findings indicate that C<italic toggle="yes">p</italic>E@BMV treatment effectively clears the pathogen and facilitates the transition of mice from the pro-inflammatory phase to the anti-inflammatory phase. Additionally, GO network analysis revealed the C<italic toggle="yes">p</italic>E@BMV-treated group had a higher response in adaptive immune compared to the PBS-treated group (Fig.&#160;<xref rid="Fig6" ref-type="fig">6c, d</xref>), aligning with the results from flow cytometry (Fig.&#160;<xref rid="Fig5" ref-type="fig">5d&#8211;k</xref>), further confirming enhanced adaptive immunity in the C<italic toggle="yes">p</italic>E@BMV-treated group.</p><p id="Par31">Of note, it has been clear that the healthy lungs have a unique microbiota which includes around 100 different taxa. Disruption of this microbial balance, known as dysbiosis, occurs during bacterial infections, as evidenced in the 2bRAD-M results (Fig.&#160;<xref rid="Fig6" ref-type="fig">6g&#8211;i</xref>). The C<italic toggle="yes">p</italic>E@BMV treatment successfully reconfigured the lung microbiota from an infected state, similar to the PBS-treated group, to a healthy mouse status. This transformation is supported by the changes in microbiota composition and abundance (Fig.&#160;<xref rid="Fig6" ref-type="fig">6g&#8211;i</xref>), along with the quantification of pneumonia-causing pathogens in lung tissue (Fig.&#160;<xref rid="Fig5" ref-type="fig">5b</xref>). Lung microbiota not only influences microbial diversity and taxonomy abundance but also plays a crucial role in immune responses. Consequently, the reshaping of the microbiota further contributed to the recovery from pneumonia.</p></sec><sec id="Sec12"><title>Methods</title><sec id="Sec13"><title>Materials and reagents</title><p id="Par32">Ciprofloxacin (Cip, 97%) was purchased from Bidepharm (Shanghai, China). Ellagic acid (EA) was purchased from J&amp;K Scientific (Beijing, China). H<sub>2</sub>O<sub>2</sub>, &#8226;OH, &#8226;O<sub>2</sub><sup>&#8211;</sup> kits were purchased from Jiancheng Bioengineering Institute (Nanjing, China). Nile red (95%), ammonium persulfate (97%), 2,2-Diphenyl-1-picrylhydrazyl (DPPH, 95%), N, N, N&#8242;, N&#8242;-Tetramethylethylenediamine (TEMED, 95%) were purchased from Macklin (Shanghai, China). SDS-PAGE, Hoechst 33,342, and 4&#8242;,6-diamidino-2-phenylindole (DAPI, 95%) were purchased from Thermo Fisher (Shanghai, China). Dil (95%), bicinchoninic acid (BCA) kits, 30% Acr-Bis (29:1), sodium 1-dodecanesulfonate (SDS), RIPA lysate, coomassie blue, and cell counting kit-8 (CCK-8) were purchased from Beyotime (Shanghai, China). Cy5 (Sulfo-Cyanine5, 95%) was purchased from MedChemExpress (New Jersey, USA). Anti-mouse CD16/32 antibody (Clone: 93), anti-mouse CD3-FITC (Clone: 17A2), anti-mouse CD4-BV421 (Clone: RM4-4), anti-mouse CD8a-APC (Clone: 53-6.7), anti-mouse Foxp3-PE (Clone: MF-14), anti-mouse CD19-APC (Clone: 6D5), anti-mouse CD138-APC (Clone: 281-2), anti-mouse CD86-BV421 (Clone: GL-1), anti-mouse CD80-APC (Clone: 16-10A1), anti-mouse CD11c-FITC (Clone: N418), anti-mouse CD206-FITC (Clone: C068C2), anti-mouse CD86-BV421 (Clone: GL-1) and anti-mouse F4/80-APC (Clone: BM8) were purchased from BioLegend (California, USA). Dulbecco&#8217;s Modified Eagle Medium (DMEM), penicillin-streptomycin, phosphate-buffered saline (PBS), and fetal bovine serum (FBS) were purchased from Gibco Life Technologies, Inc. (Grand Island, USA). Mouse TNF-&#945;, IL-1&#946;, IL-6, IL-10 ELISA kits, and macrophage colony-stimulating factor 1 (M-CSF) were purchased from iCell Bioscience Inc. (Shanghai, China). Bovine serum albumin (BSA) and Triton-X-100 were purchased from Solarbio Science &amp; Technology Co., Ltd. (Beijing, China).</p></sec><sec id="Sec14"><title>Bacterial strains</title><p id="Par33"><italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup>, <italic toggle="yes">E. coli</italic> Xen14 (PerkinElmer Inc., Waltham, MA, USA), <italic toggle="yes">E. coli</italic> DH5&#945;, and <italic toggle="yes">S. typhimurium</italic> 15,649 were employed in this study. <italic toggle="yes">S. typhimurium</italic> 15,649 was kindly provided by Zhou Lab at the First Affiliated Hospital of Wenzhou Medical University. For experiments, one colony of <italic toggle="yes">E. coli</italic> DH5&#945; on lysogeny broth (LB, OXOID, Basingstoke, UK) plates was inoculated into 10&#8201;mL of LB at 37&#8201;&#176;C for 24&#8201;h in ambient air. Preculture was diluted 1:20 in 200&#8201;mL LB and grown statically (37&#8201;&#176;C, 16&#8201;h) for the main culture to harvest bacteria. <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> with green fluorescence and <italic toggle="yes">E. coli</italic> Xen14 with bioluminescence are multidrug-resistant strains cultured at 37&#8201;&#176;C under ambient atmosphere in tryptone soy broth (TSB, OXOID, Basingstoke, UK) or LB medium, respectively. Bacteria were cultured using the same protocol described above, with plate growth and preculture performed in medium containing strain-specific antibiotics: 10&#8201;&#956;g/mL tetracycline for <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> or 30&#8201;&#956;g/mL kanamycin for <italic toggle="yes">E. coli</italic> Xen14. <italic toggle="yes">S. typhimurium</italic> 15,649 was incubated for 24&#8201;h at 37&#8201;&#176;C, followed by main culture using the same protocol described above. Finally, bacteria were harvested by centrifugation at 5000&#8201;g for 5&#8201;min. The collected bacteria were washed twice in PBS (10&#8201;mL, 5&#8201;mM K<sub>2</sub>HPO<sub>4</sub>, 5&#8201;mM KH<sub>2</sub>PO<sub>4</sub>, and 150&#8201;mM NaCl, pH 7.4), and bacterial concentration was determined in a B&#252;rker-T&#252;rk counting chamber.</p></sec><sec id="Sec15"><title>Cell lines</title><p id="Par34">Murine macrophage cell line (RAW264.7) and mouse fibroblast (L929) cells were involved in this study and were purchased from the American Type Culture Collection (ATCC). RAW264.7 and L929 cells were cultured in DMEM containing 10% FBS and 1% penicillin&#8722;streptomycin solution.</p></sec><sec id="Sec16"><title>Animals</title><p id="Par35">Female BALB/c mice (6&#8211;8 weeks) were provided by Vital River Laboratory Animal Technology Co., Ltd (Beijing, China). The mice were housed under controlled conditions (20&#8201;&#177;&#8201;2&#8201;&#176;C, 50% humidity, and 12/12 light cycle). Experiments followed the guidelines outlined in the Guide for the Care and Use of Laboratory Animals. All animal studies were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee at Wenzhou Institute, University of Chinese Academy of Sciences (No. WIUCAS22081605, WIUCAS25010207).</p></sec><sec id="Sec17"><title>Preparation of bacterial membrane</title><p id="Par36">The collected and lyophilized <italic toggle="yes">E. coli</italic> DH5&#945; (2&#8201;g) was dispersed in Tris-HCl buffer (40&#8201;mL, 20&#8201;mM, pH 8.0) containing lysozyme (15&#8201;mg/mL). The samples were incubated at 37&#8201;&#176;C under constant shaking for 3&#8201;h. Subsequently, the bacterial solution was incubated with 400&#8201;mg SDS and disrupted using a probe sonicator while cooling in an ice/water bath before being lyophilized. The resulting dried bacteria lysate was suspended in a mixture of chloroform-methanol-water (5&#8201;mL, 30:15:1, v/v/v), placed on a shaker at 37&#8201;&#176;C for 1&#8201;h, and then filtered by Millipore HVLP Durapore&#174; membrane (0.45&#8201;&#956;m). The residue was extracted by chloroform-methanol-water three more times, and then the filtrate was combined and dried under vacuum to yield BMV (0.58&#8201;g, yield: 29%). The yield (%) was determined by dividing the weight of BMV by the total bacterial weight. Finally, the protein concentration of the bacterial membrane was determined using the BCA assay.</p></sec><sec id="Sec18"><title>Synthesis of Cip-<italic toggle="yes">pba</italic>-EA prodrug</title><p id="Par37">The <italic toggle="yes">phenylboronic acid</italic>-functionalized ciprofloxacin (Cip-<italic toggle="yes">pba</italic>) was synthesized according to our previous report<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Briefly, ciprofloxacin (Cip, 252&#8201;mg, 0.73&#8201;mmol) and K<sub>2</sub>CO<sub>3</sub> (300&#8201;mg, 2.17&#8201;mmol) were dissolved in DMF/H<sub>2</sub>O (4.0&#8201;mL, v/v&#8201;=&#8201;2/1), followed by the addition of 4-(bromomethyl)-phenylboronic acid (163&#8201;mg, 1.35&#8201;mmol). The reaction mixture was allowed to react overnight. The pH of the solution was adjusted to 7.4 using an HCl solution. Subsequently, the precipitation was filtered and dried under a vacuum to obtain the white powder. <sup>1</sup>H NMR (400&#8201;MHz, DMSO-d<sub>6</sub>) of Cip-<italic toggle="yes">pba</italic>: 1H NMR (400&#8201;MHz, DMSO) &#948; 15.18 (s, 1H), 8.67 (s, 1H), 8.01 (s, 2H), 7.91 (d, <italic toggle="yes">J</italic>&#8201;=&#8201;13.3&#8201;Hz, 1H), 7.79 (d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.8&#8201;Hz, 2H), 7.58 (d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.4&#8201;Hz, 1H), 7.33 (d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.7&#8201;Hz, 2H), 3.83 (s, 1H), 3.59 (s, 2H), 2.62 (s, 4H), 1.33 (d, <italic toggle="yes">J</italic>&#8201;=&#8201;6.4&#8201;Hz, 2H), 1.19 (s, 2H).</p><p id="Par38">The conjugated prodrug, Cip-<italic toggle="yes">pba</italic>-Ea was synthesized by a dynamic covalent bond. Briefly, Cip-<italic toggle="yes">pba</italic> (5.0&#8201;mg, 10.0&#8201;&#956;mol) and Ea (1.5&#8201;mg, 5.0&#8201;&#956;mol) were reacted in DMSO (500&#8201;&#956;L) under stirring at 25&#8201;&#176;C for 12&#8201;h. The resulting product is denoted as C<italic toggle="yes">p</italic>E. The chemical structure of C<italic toggle="yes">p</italic>E was verified by <sup>1</sup>H&#8211;<sup>1</sup>H COSY and <sup>1</sup>H&#8211;<sup>1</sup>H NOSY spectra using NMR spectroscopy (AVANCE III 400&#8201;MHz, Bruker, Germany) in methanol-<italic toggle="yes">d</italic><sub>4</sub>, mass spectrum (Agilent 6520Q, California, USA), Fourier infrared spectrometer (Bruker Tensor II, Karlsruhe, Germany) and UV-vis spectrum (UV-1900i, Shimadzu, Japan).</p></sec><sec id="Sec19"><title>Preparation of C<italic toggle="yes">p</italic>E@BMV</title><p id="Par39">Cip-<italic toggle="yes">pba</italic> (5.0&#8201;mg, 10.0&#8201;&#956;mol) and Ea (1.5&#8201;mg, 5.0&#8201;&#956;mol) were reacted in DMSO (500&#8201;&#956;L) under stirring at 25&#8201;&#176;C for 12&#8201;h. The resulting product C<italic toggle="yes">p</italic>E was coated with BMV through extrusion. In brief, C<italic toggle="yes">p</italic>E (100&#8201;&#956;L, 13&#8201;mg/mL) and BMV (900&#8201;&#956;L, 500&#8201;&#956;g/mL in ultrapure water) were mixed, and a noticeable Tyndall effect was observed immediately. Then, the mixture of BMV and C<italic toggle="yes">p</italic>E was extruded 20 times successively through a 200&#8201;nm polycarbonate porous membrane with an Avanti mini extruder to obtain the C<italic toggle="yes">p</italic>E@BMV, and the C<italic toggle="yes">p</italic>E@BMV was kept at 4&#8201;&#176;C for further use.</p><p id="Par40">In addition, the Dil-labeled C<italic toggle="yes">p</italic>E@BMV (C<italic toggle="yes">p</italic>E@BMV<sup>Dil</sup>) was prepared by adding Dil (3%, w/w of BMV) to the BMV, followed by mixing with C<italic toggle="yes">p</italic>E according to a similar protocol as described above. The free Dil was removed by centrifugation. For the preparation of Cy5- or Nile Red-labeled CpE@BMV (C<italic toggle="yes">p</italic>E<sub>Cy5</sub>@BMV or <sup>Nile red</sup>C<italic toggle="yes">p</italic>E@BMV), Cy5 (3%, w/w of Cip-pba) or Nile Red (3%, w/w of Cip-<italic toggle="yes">pba</italic>) was added during C<italic toggle="yes">p</italic>E formation, and a similar protocol was used to prepare C<italic toggle="yes">p</italic>E<sub>Cy5</sub>@BMV or <sup>Nile Red</sup>C<italic toggle="yes">p</italic>E@BMV. Free Cy5 or Nile Red was removed by centrifugation. The C<italic toggle="yes">p</italic>E<sub>Cy5</sub>@BMV<sup>Dil</sup> was prepared by adding Dil (3%, w/w of BMV) to the BMV, followed by mixing with Cy5-labeled C<italic toggle="yes">p</italic>E (3%, w/w) using a similar protocol. Free Cy5 and Dil were removed by centrifugation.</p><p id="Par41">The loading content and encapsulation efficiency of Cip and Ea were determined by HPLC.<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="d33e2973">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{\rm{LC}}}}\,(\%)=\frac{{{{\rm{Weight}}}}\; {{{\rm{of}}}}\; {{{\rm{Cip}}}}\; {{{\rm{in}}}}\; {{Cp}}{{{\rm{E@BMV}}}}}{{{{\rm{Weight}}}}\; {{{\rm{of}}}}\; {{{\rm{Cip}}}}-{{{\rm{loaded}}}}\; Cp{{{\rm{E@BMV}}}}} \times 100\%$$\end{document}</tex-math><mml:math id="d33e2979"><mml:mi mathvariant="normal">LC</mml:mi><mml:mspace width="0.25em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>%</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Weight</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">Cip</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">in</mml:mi><mml:mspace width="0.16em"/><mml:mi>C</mml:mi><mml:mi>p</mml:mi><mml:mi mathvariant="normal">E@BMV</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Weight</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">Cip</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="normal">loaded</mml:mi><mml:mspace width="0.16em"/><mml:mi>C</mml:mi><mml:mi>p</mml:mi><mml:mi mathvariant="normal">E@BMV</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mi>%</mml:mi></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41467_2025_60570_Article_Equ1.gif"/></alternatives></disp-formula><disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="d33e3028">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{\rm{EE}}}}\, (\%)=\frac{{{{\rm{Weight}}}}\; {{{\rm{of}}}}\; {{{\rm{Cip}}}}\; {{{\rm{in}}}}\; {{Cp{{{\rm{E}}}}{{{\rm{@BMV}}}}}}}{{{{\rm{Weight}}}}\; {{{\rm{of}}}}\; {{{\rm{Cip}}}}\; {{{\rm{added}}}}}\times 100\%$$\end{document}</tex-math><mml:math id="d33e3034"><mml:mi mathvariant="normal">EE</mml:mi><mml:mspace width="0.25em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>%</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Weight</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">Cip</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">in</mml:mi><mml:mspace width="0.16em"/><mml:mi>C</mml:mi><mml:mi>p</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">@BMV</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Weight</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">Cip</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">added</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mi>%</mml:mi></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41467_2025_60570_Article_Equ2.gif"/></alternatives></disp-formula></p></sec><sec id="Sec20"><title>Characterization of C<italic toggle="yes">p</italic>E@BMV</title><p id="Par42">The size distribution, colloidal stability, and zeta potential were measured using Malvern Nano ZS Zen3600 (Malvern, UK). For size and Zeta potential measurement, C<italic toggle="yes">p</italic>E and C<italic toggle="yes">p</italic>E@BMV were diluted with phosphate buffer (PB, pH 7.4, 10&#8201;mM) to a final concentration of approximately 0.1&#8201;mg/mL. The sample morphology was observed by transmission electron microscope (TEM, FEI Talos-F200S, Hillsboro, USA) with an accelerating voltage of 120&#8201;kV. EDS mapping was used to analyze the spatial distribution of various elements.</p><p id="Par43">To determine the BMV coating, the membrane proteins of C<italic toggle="yes">p</italic>E@BMV were identified through sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). In brief, the obtained C<italic toggle="yes">p</italic>E@BMV was incubated with RIPA lysate (1:100, v/v) for 30&#8201;min on ice and subsequently centrifuged (15,000&#8201;g, 4&#8201;&#176;C) for 20&#8201;min to isolate the membrane protein. Total protein concentration was determined using the BCA protein assay kit. Equivalent amounts of total proteins from BMV and C<italic toggle="yes">p</italic>E@BMV were denatured by boiling in an SDS loading buffer at 99&#8201;&#176;C for 15&#8201;min, and C<italic toggle="yes">p</italic>E was treated similarly as a control. All samples were separated by electrophoresis on a 10% SDS-PAGE gel, further stained with Coomassie blue for 2&#8201;h, and decolorized overnight before being photographed using a mobile phone camera. In addition, C<italic toggle="yes">p</italic>E<sub>Cy5</sub>@BMV, C<italic toggle="yes">p</italic>E@BMV<sup>Dil</sup>, or C<italic toggle="yes">p</italic>E<sub>Cy5</sub>@BMV<sup>Dil</sup> were analyzed by flow cytometry (Beckman CytoFlex, California, USA) to prove the BMV coating.</p></sec><sec id="Sec21"><title>Molecular dynamics simulation</title><p id="Par44">In order to understand the experimental results from a microscopic perspective, all-atom simulations were carried out to investigate the self-assembly of C<italic toggle="yes">p</italic>E molecules and their interactions with the outer membrane of Gram-negative bacteria. Similar to our previous work<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>, we used the ATB tool<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> to build an all-atom model of the C<italic toggle="yes">p</italic>E molecule, employed the CHARMM-GUI tool<sup><xref ref-type="bibr" rid="CR66">66</xref></sup> to build a model of the outer membrane of Gram-negative bacteria<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>, and then adopted the combination rule to construct the hybrid system of these two parts.</p><p id="Par45">To prepare the initial configurations for self-assembly simulations, the Gromacs insert-molecules tool was employed. Fifty C<italic toggle="yes">p</italic>E molecules were randomly positioned within a periodic cubic box with a side length of 15&#8201;nm. The system was then solvated with TIP3P water molecules to mimic a realistic biological environment. To maintain the electrical neutrality of the system, calcium and chloride ions were strategically added by replacing water molecules at random until a concentration of 0.1&#8201;M was achieved. Finally, to promote the formation of the most stable self-assembled structure, an annealing simulation was conducted for 100&#8201;ns. During this process, the temperature of the system was gradually decreased from 450&#8201;K to 298.15&#8201;K. Nose-Hoover thermostat and isotropic Parrinello&#8211;Rahman barostat were utilized throughout the simulation to maintain the desired temperature and pressure conditions.</p><p id="Par46">To study how C<italic toggle="yes">p</italic>E molecules interact with the outer membrane of Gram-negative bacteria, they were initially positioned under the outer membrane. Then the system evolves freely for 100&#8201;ns under constant temperature and pressure conditions. The conformational changes were examined and analyzed after the simulation. The simulations were run with Gromacs version 2021.4 and analyzed with VMD software<sup><xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>.</p></sec><sec id="Sec22"><title>Evaluation of ROS scavenging</title><p id="Par47">Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) scavenging assay: the H<sub>2</sub>O<sub>2</sub> scavenging capacity of C<italic toggle="yes">p</italic>E@BMV was evaluated using a hydrogen peroxide assay kit. Briefly, Amplite IR peroxidase substrate and peroxidase were mixed to prepare the working solution according to the protocol. Then, C<italic toggle="yes">p</italic>E@BMV (50&#8201;&#956;L, at different concentrations of 16, 31, 62, 125, and 250&#8201;&#956;g/mL) was added to the working solution (50&#8201;&#956;L) at room temperature. After 30&#8201;min, the solution was measured using a microplate reader with the fluorescence mode (Ex/Em: 640&#8201;nm/680&#8201;nm). The inhibition rate was calculated based on an H<sub>2</sub>O<sub>2</sub> standard curve.</p><p id="Par48">Hydroxyl radical (&#8226;OH) scavenging test: a hydroxyl free radical assay kit was used to study the &#8226;OH scavenging capacity of C<italic toggle="yes">p</italic>E@BMV. Briefly, C<italic toggle="yes">p</italic>E@BMV (200&#8201;&#956;L, at different concentrations of 16, 31, 62, 125, and 250&#8201;&#956;g/mL) was added into a fluorescence solution (200&#8201;&#956;L) and incubated for 1&#8201;min at 37&#8201;&#176;C. Then, hydroxyl radical initiator and Fenton reagent were added and incubated for 20&#8201;min at 25&#8201;&#176;C. The absorbance of samples at 550&#8201;nm was recorded with a microplate reader. The inhibition rate was calculated based on a standard curve.</p><p id="Par49">Superoxide anion (&#8226;O<sub>2</sub><sup>&#8211;</sup>) scavenging assay: the &#8226;O<sub>2</sub><sup>&#8211;</sup> scavenging capacity of C<italic toggle="yes">p</italic>E@BMV was evaluated using a superoxide anion assay kit. Briefly, C<italic toggle="yes">p</italic>E@BMV (20&#8201;&#956;L, at different concentrations of 16, 31, 62, 125, and 250&#8201;&#956;g/mL) was mixed with 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium sodium salt (WST-1) working solution (200&#8201;&#956;L). Subsequently, xanthine oxidase solution (20&#8201;&#956;L) was added to each tube and incubated for 10&#8201;min at 37&#8201;&#176;C. The absorbance of samples at 550&#8201;nm was recorded with a microplate reader. The inhibition rate was calculated based on a standard curve.</p><p id="Par50">ABTS&#8226;&#183;radical scavenging activity: ABTS&#8226; was added to potassium persulfate to produce an ABTS radical cation (ABTS&#8201;+&#8201;&#8226;). Then, C<italic toggle="yes">p</italic>E@BMV nanoparticles (100&#8201;&#956;L, at different concentrations of 16, 31, 62, 125, and 250&#8201;&#956;g/mL) were added to the ABTS&#8201;+&#8201;&#8226; solution. The absorbance of both ABTS&#8201;+&#8201;&#8226; solution (A<sub>B</sub>) and the mixture solution containing ABTS&#8201;+&#8201;&#8226; and C<italic toggle="yes">p</italic>E@BMV nanoparticles (A<sub>E</sub>) was measured at 734&#8201;nm. The percentage scavenging of ABTS&#8201;+&#8201;&#8226; was calculated as follows:<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="d33e3228">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{\rm{Scavenging\; efficiency}}}}=\frac{{{{{\rm{A}}}}}_{{{{\rm{B}}}}}-{{{{\rm{A}}}}}_{{{{\rm{E}}}}}}{{{{{\rm{A}}}}}_{{{{\rm{B}}}}}}\times 100\%$$\end{document}</tex-math><mml:math id="d33e3234"><mml:mi mathvariant="normal">Scavenging efficiency</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mi>%</mml:mi></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41467_2025_60570_Article_Equ3.gif"/></alternatives></disp-formula></p><p id="Par51">DPPH&#8226; scavenging assay: C<italic toggle="yes">p</italic>E@BMV nanoparticles (100&#8201;&#956;L, at different concentrations of 16, 31, 62, 125, and 250&#8201;&#956;g/mL) were incubated with DPPH ethanol solution (0.1&#8201;mM, 100&#8201;&#956;L) for 30&#8201;min. The absorbance of DPPH&#8226; solution (A<sub>c</sub>), C<italic toggle="yes">p</italic>E@BMV nanoparticles (A<sub>d</sub>), and the mixture solution containing DPPH&#8226; and C<italic toggle="yes">p</italic>E@BMV nanoparticles (A<sub>s</sub>) was measured at 517&#8201;nm. The percentage scavenging of DPPH&#8226; was calculated as follows:<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="d33e3285">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{\rm{Scavenging\; efficiency}}}}=1-\frac{{{{{\rm{A}}}}}_{{{{\rm{s}}}}}-{{{{\rm{A}}}}}_{{{{\rm{d}}}}}}{{{{{\rm{A}}}}}_{{{{\rm{c}}}}}}\times 100\%$$\end{document}</tex-math><mml:math id="d33e3291"><mml:mi mathvariant="normal">Scavenging efficiency</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mi>%</mml:mi></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41467_2025_60570_Article_Equ4.gif"/></alternatives></disp-formula></p></sec><sec id="Sec23"><title>ROS scavenging capability of C<italic toggle="yes">p</italic>E@BMV in vitro</title><p id="Par52">RAW264.7 cells (1&#8201;&#215;&#8201;10&#8309; cells/well) were plated in 24-well plates and cultured for 24&#8201;h (37&#8201;&#176;C, 5% CO&#8322;). After PBS washing, the cells were cultured with LPS (200&#8201;ng/mL, 24&#8201;h). The cells were treated with Cip (4.4&#8201;&#956;g/mL), C<italic toggle="yes">p</italic>E (8.2&#8201;&#956;g/mL), BMV (2.8&#8201;&#956;g/mL), and C<italic toggle="yes">p</italic>E@BMV (with Cip concentration of 4.4&#8201;&#956;g/mL) for 24&#8201;h, and further incubated with DCFH-DA (10&#8201;&#956;M) for 30&#8201;min. Meanwhile, the cell nuclei were stained with Hoechest33324 and imaged on a confocal laser scanning microscope (CLSM, Nikon A1, Japan), with the excitation of 405/488&#8201;nm, collecting fluorescence at 420&#8211;460&#8201;nm (DAPI) and 500&#8211;535&#8201;nm (DCFH-DA). In parallel experiments, culture supernatants were analyzed for inflammatory cytokines of IL-6, IL-1&#946;, TNF-&#945;, and IL-10 using ELISA kits according to the protocols.</p></sec><sec id="Sec24"><title>Cell-protective ability of C<italic toggle="yes">p</italic>E@BMV against LPS and H<sub>2</sub>O<sub>2</sub> damage</title><p id="Par53">RAW264.7 cells were plated in 96-well plates (1&#8201;&#215;&#8201;10<sup>4</sup> cells/well) and cultured overnight. The LPS (2&#8201;&#956;g/mL) or H<sub>2</sub>O<sub>2</sub> (1&#8201;mM) was added to cells for 2&#8201;h. The cells were then treated with Cip (4.4&#8201;&#956;g/mL), Ea (1.9&#8201;&#956;g/mL), BMV (2.8&#8201;&#956;g/mL), and C<italic toggle="yes">p</italic>E@BMV (with Cip concentration of 4.4&#8201;&#956;g/mL) for 24&#8201;h. The treated RAW264.7 cells of all groups were harvested, and the cell viability was assessed using CCK-8 kits according to the protocols.</p></sec><sec id="Sec25"><title>Red blood cell hemolysis analysis</title><p id="Par54">Mouse whole blood (1&#8201;mL) was diluted in PBS (1:10), centrifuged (4000&#8201;&#215;&#8201;<italic toggle="yes">g</italic>, 15&#8201;min), and washed with PBS (10&#8201;mL&#8201;&#215;&#8201;5) to collect red blood cells (RBCs). The RBCs were resuspended to 4% (v/v) in PBS. Serial dilutions of CpE@BMV (4&#8211;400&#8201;&#956;g/mL) were incubated with 4% RBC suspensions (1:1&#8201;v/v) for 3&#8201;h at 37&#8201;&#176;C. After centrifugation (3000&#8201;&#215;&#8201;<italic toggle="yes">g</italic>, 15&#8201;min), supernatant absorbance (OD<sub>treated</sub>, 545&#8201;nm) was measured to calculate hemolysis. The PBS was used as a negative control (OD <sub>negative control</sub>) and 0.1% Triton-X as a positive control (OD <sub>positive control</sub>). The percentage of hemolysis was determined using the formula:<disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="d33e3379">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{\rm{Hemolysis\; ratio}}}}\,(\%)=\frac{{{{{\rm{OD}}}}}_{{{{\rm{treated}}}}}-{{{{\rm{OD}}}}}_{{{{\rm{negative\; control}}}}}}{{{{{\rm{OD}}}}}_{{{{\rm{positive\; control}}}}}-{{{{\rm{OD}}}}}_{{{{\rm{negative\; control}}}}}}\times 100\%$$\end{document}</tex-math><mml:math id="d33e3385"><mml:mi mathvariant="normal">Hemolysis ratio</mml:mi><mml:mspace width="0.25em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>%</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">OD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">treated</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">OD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">negative control</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">OD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">positive control</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">OD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">negative control</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mi>%</mml:mi></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41467_2025_60570_Article_Equ5.gif"/></alternatives></disp-formula></p></sec><sec id="Sec26"><title>Cip and Ea release from C<italic toggle="yes">p</italic>E@BMV</title><p id="Par55">The release profile of Cip and Ea from C<italic toggle="yes">p</italic>E@BMV was evaluated by dialysis and measured by a High-performance liquid chromatography system (HPLC, Agilent, US). A solution of C<italic toggle="yes">p</italic>E@BMV (1&#8201;mL, [Cip]&#8201;=&#8201;350&#8201;&#956;g/mL, [Ea]&#8201;=&#8201;150&#8201;&#956;g/mL) was transferred into a dialysis bag (MWCO 3000&#8201;Da), and suspended in different buffers at 37&#8201;&#176;C in an incubator: PBS (20&#8201;mL, 10&#8201;mM) at pH 7.4, PBS (20&#8201;mL, 10&#8201;mM) at pH 6.5, PBS (20&#8201;mL, 10&#8201;mM) at pH 7.4 containing H<sub>2</sub>O<sub>2</sub> (100&#8201;&#956;M), PBS (20&#8201;mL, 10&#8201;mM) at pH 6.5 containing H<sub>2</sub>O<sub>2</sub> (100&#8201;&#956;M). The elevated concentration of H&#8322;O&#8322; at the infection site, which can reach up to 1&#8201;mM, is a result of the oxidative burst generated by immune cells to combat invading pathogens. This serves as a critical component of the host&#8217;s defense mechanism<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>. At predetermined intervals, samples (3&#8201;mL) were withdrawn from the buffer solution and replaced with fresh isopycnic phosphate buffer. All collected solutions were lyophilized and resolved in DMSO to measure the content of Cip and Ea using the HPLC. HPLC analysis was conducted using an Agilent 1260 Infinity II HPLC system (Agilent, US) with an Alltima C18 column (4.6&#8201;&#215;&#8201;100&#8201;mm, 2.7&#8201;&#956;m). The UV detection was set at 280&#8201;nm, with a mobile phase of 2% acetic acid in water/ACN (84:16, v/v). The flow rate was 0.7&#8201;mL/min, and the injection volume was 5&#8201;&#956;L.</p></sec><sec id="Sec27"><title>MIC and MBC determination</title><p id="Par56">We tested minimum inhibitory concentration (MIC) as well as bactericidal concentration (MBC) values of the tested formulations according to our published protocal<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR72">72</xref></sup>. Briefly, Cip, Ea, C<italic toggle="yes">p</italic>E, and C<italic toggle="yes">p</italic>E@BMV (100&#8201;&#956;L) with an equivalent amount of Cip ranging from 0 to 7.0&#8201;&#956;g/mL and an equivalent amount of Ea ranging from 0 to 3.0&#8201;&#956;g/mL were applied to suspensions of <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> (in TSB), <italic toggle="yes">E. coli</italic> Xen14, and <italic toggle="yes">S. typhimurium</italic> 15,649 (in LB) (100&#8201;&#956;L, 2&#8201;&#215;&#8201;10<sup>5</sup> bacteria/mL). The MIC values represented the lowest antibiotic concentrations preventing visible growth. The MBC values were tested by plating aliquots (10&#8201;&#956;L) from wells showing no visible growth on agar plates after incubation for 24&#8201;h at 37&#8201;&#176;C, and the lowest concentration at which colony formation remained absent was considered as the MBC value.</p></sec><sec id="Sec28"><title>Macrophage phenotypic regulation of C<italic toggle="yes">p</italic>E@BMV in vitro</title><p id="Par57">RAW264.7 cells were plated in 24-well plates (5&#8201;&#215;&#8201;10<sup>4</sup> cells/well) and cultured overnight. Treatments included PBS, Cip (4.4&#8201;&#956;g/mL), Ea (1.9&#8201;&#956;g/mL), and C<italic toggle="yes">p</italic>E@BMV (with the concentration of Cip 4.4&#8201;&#956;g/mL and Ea 1.9&#8201;&#956;g/mL) for 12&#8201;h. The treated RAW264.7 cells of all groups were harvested and blocked with anti-mouse CD16/32 antibody (10&#8201;&#956;L, 0.5&#8201;mg/mL) for Fc receptors. Subsequently, the cell surface was stained with anti-mouse F4/80-APC (10&#8201;&#956;L, 0.5&#8201;mg/mL) and anti-mouse CD86-BV421 (10&#8201;&#956;L, 0.5&#8201;mg/mL), while the intracellular staining was performed using anti-mouse CD206-FITC (10&#8201;&#956;L, 0.5&#8201;mg/mL) for flow cytometry (Beckman CytoFlex, California, USA). In addition, cytokine levels of IL-6, IL-1&#946;, TNF-&#945;, and IL-10 in the cell supernatant were measured using ELISA kits according to the protocols.</p></sec><sec id="Sec29"><title>Cellular uptake of C<italic toggle="yes">p</italic>E@BMV by <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> infected RAW264.7 cells in vitro</title><p id="Par58">The cell uptake of C<italic toggle="yes">p</italic>E, C<italic toggle="yes">p</italic>E@BMV by <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> infected RAW264.7 cells was studied. Briefly, RAW264.7 cells were plated in six-well plates and grown for 12&#8201;h at 37&#8201;&#176;C (4&#8201;&#215;&#8201;10<sup>5</sup>&#8201;cells/mL). The cell was mixed with <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> (8&#8201;&#215;&#8201;10<sup>6</sup> bacteria/well) for 4&#8201;h. Gentamicin (100&#8201;&#956;g/mL) was then added to inhibit extracellular growth during 24&#8201;h of coculture. Following coculture, wells were gently washed once with PBS to remove extracellular <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup>. The freshly prepared Nile red-loaded C<italic toggle="yes">p</italic>E or C<italic toggle="yes">p</italic>E@BMV (with the concentration of Cip 0.44&#8201;&#956;g/mL) were cocultured with cells for another 2&#8201;h. Cells were washed with PBS (1&#8201;mL/well), fixed with 4% paraformaldehyde (15&#8201;min, room temperature), and stained with 4&#8242;,6-diamidino-2-phenylindole (10&#8201;&#956;M, 30&#8201;min, in the dark). RAW264.7 cells containing internalized red-fluorescent C<italic toggle="yes">p</italic>E or C<italic toggle="yes">p</italic>E@BMV were visualized using confocal laser scanning microscopy (A1, Nikon, Japan), with the excitation of 405/525&#8201;nm, collecting fluorescence at 420&#8211;460&#8201;nm (DAPI) and 560&#8211;625&#8201;nm (Nile red). Furthermore, the red fluorescence intensity in infected macrophages was detected using flow cytometry (Beckman CytoFlex, California, USA).</p></sec><sec id="Sec30"><title>Live/dead staining of bacteria in vitro</title><p id="Par59"><italic toggle="yes">E. coli</italic> Xen14 was seeded onto a confocal dish and incubated with Cip, C<italic toggle="yes">p</italic>E, and C<italic toggle="yes">p</italic>E@BMV (with the concentration of Cip 0.44&#8201;&#956;g/mL) for 6&#8201;h. Subsequently, the bacteria were stained with SYTO 9 (green, for live bacteria) and PI (red, for dead bacteria) for 30&#8201;min before being observed using confocal laser scanning microscopy (A1, Nikon, Japan), with the excitation of 488/525&#8201;nm, collecting fluorescence at 420&#8211;460&#8201;nm (SYTO 9) and 560&#8211;625&#8201;nm (PI). Meanwhile, the bacteria were treated with the treatment of PBS as the control group.</p></sec><sec id="Sec31"><title>Antibacterial activity against extracellular and intracellular bacteria in RAW264.7 cells in vitro</title><p id="Par60">For extracellular bacteria eradication in vitro: RAW264.7 cells were seeded at a 1.5&#8201;&#215;&#8201;10<sup>5</sup>&#8201;cells/well density in 24-well plates and grown for 24&#8201;h at 37&#8201;&#176;C. The cells were infected by <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> or <italic toggle="yes">E. coli</italic> Xen14 (3&#8201;&#215;&#8201;10<sup>6</sup> bacteria/well) for 2&#8201;h. After washing the cells with PBS (1&#8201;mL&#8201;&#215;&#8201;3), the infected macrophage cells were treated with Cip, Cip-<italic toggle="yes">pba</italic>, C<italic toggle="yes">p</italic>E, and C<italic toggle="yes">p</italic>E@BMV (with the concentration of Cip 0.44&#8201;&#956;g/mL) for 12&#8201;h, 24&#8201;h, and 48&#8201;h, respectively. The supernatant was collected, and the extracellular <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> or <italic toggle="yes">E. coli</italic> was measured by serial dilution and plated on TSB or LB agar for c.f.u. enumeration.</p><p id="Par61">For intracellular bacteria eradication in vitro: RAW264.7 cells were seeded at a 1.5&#8201;&#215;&#8201;10<sup>5</sup>&#8201;cells/well density in 24-well plates and grown for 24&#8201;h at 37&#8201;&#176;C. RAW264.7 cells were infected with <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> or <italic toggle="yes">E. coli</italic> Xen14 (3&#8201;&#215;&#8201;10<sup>6</sup> bacteria/well) for 2&#8201;h. The cells were washed with PBS (1&#8201;mL&#8201;&#215;&#8201;3) to remove the extracellular bacteria. The infected macrophage cells were treated with Cip, Cip-<italic toggle="yes">pba</italic>, C<italic toggle="yes">p</italic>E, and C<italic toggle="yes">p</italic>E@BMV (with the concentration of Cip 0.44&#8201;&#956;g/mL) for 12&#8201;h, 24&#8201;h, and 48&#8201;h, respectively. Cells were collected through centrifugation (1000&#8201;&#215;&#8201;<italic toggle="yes">g</italic>, 3&#8201;min) and lysed in PBS supplemented with 0.1% bovine serum albumin and 0.1% Triton-X. The harvested lysate was diluted serially and plated on TSB or LB agar for c.f.u. enumeration. The detection limit for c.f.u. was 200, using 100&#8201;&#181;L of the undiluted suspension.</p></sec><sec id="Sec32"><title>Phagocytosis assay induced by C<italic toggle="yes">p</italic>E@BMV in vitro</title><p id="Par62">RAW264.7 cells were seeded in 24-well plates (1.5&#8201;&#215;&#8201;10<sup>5</sup> cells/well) and cultured for 24&#8201;h. The cells were pretreated with Cip, Ea, and C<italic toggle="yes">p</italic>E@BMV ([Cip]&#8201;=&#8201;7.0&#8201;&#956;g/mL, [Ea]&#8201;=&#8201;3.0&#8201;&#956;g/mL, [C<italic toggle="yes">p</italic>E@BMV]&#8201;=&#8201;17.5&#8201;&#956;g/mL in which the concentration of Cip is 7.0&#8201;&#956;g/mL) for 24&#8201;h. Subsequently, the cells were cocultured with SYTO 9-labeled <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> (1.5&#8201;&#215;&#8201;10<sup>6</sup> bacteria/well) for 60&#8201;min, followed by washing with PBS and staining with Dil (10&#8201;&#956;M). Red fluorescence of RAW264.7 and green fluorescence of <italic toggle="yes">S. aureus</italic> WH<sup>GFP</sup> were detected using flow cytometry (Beckman CytoFlex, California, USA).</p></sec><sec id="Sec33"><title>Cytotoxicity of C<italic toggle="yes">p</italic>E@BMV in vitro</title><p id="Par63">L929 cells and RAW264.7 cells were cultured in a 96-well plate (1&#8201;&#215;&#8201;10<sup>4</sup> cells/well) overnight. The cells were incubated with C<italic toggle="yes">p</italic>E@BMV at different concentrations (0.1&#8211;400&#8201;&#956;g/mL) for 24&#8201;h. The cell cytotoxicity was assessed using a CCK-8 kit according to the protocol.</p></sec><sec id="Sec34"><title>Antibacterial efficacy of C<italic toggle="yes">p</italic>E@BMV in a pneumonia model</title><p id="Par64">BALB/c mice were intratracheally administered with <italic toggle="yes">E. coli</italic> Xen14 (1&#8201;&#215;&#8201;10<sup>9</sup> bacteria/mL, 50&#8201;&#956;L per mouse) to establish a pneumonia model. The mice were randomly allocated into six groups (<italic toggle="yes">n</italic>&#8201;=&#8201;7): Control group (healthy mice), the <italic toggle="yes">E. coli</italic> Xen14 infected mice with different formulations using equivalent doses of Cip, Ea, and BMV were 1.76&#8201;mg/kg, 0.76&#8201;mg/kg, and 1.12&#8201;mg/kg, respectively. Different formulations were treated via intratracheal instillation. Body weights were monitored every 48&#8201;h during treatment. At day 3 and day 7 post-treatment, the blood was collected from the eyes (<italic toggle="yes">n</italic>&#8201;=&#8201;5) to measure the major blood parameters using Mindray, Shenzhen, China, and the serum was further collected and applied for cytokine quantification (TNF-&#945;, IL-6, IL-&#946;, IL-10) with ELISA Kits. The mice were sacrificed on day 7. The heart, liver, spleen, lung, and kidney were harvested (<italic toggle="yes">n</italic>&#8201;=&#8201;3) for H&amp;E staining according to the protocol. The frozen slices of lung tissue were prepared, and the immunofluorescence staining was performed to analyze macrophage phenotypes labeled with CD86 and CD206. The lung tissue with PBS-treated and C<italic toggle="yes">p</italic>E@BMV-treated groups was also collected for RNA sequencing (<italic toggle="yes">n</italic>&#8201;=&#8201;3) and 2bRAD sequencing for microbiome (<italic toggle="yes">n</italic>&#8201;=&#8201;3). Additionally, the lung tissue (<italic toggle="yes">n</italic>&#8201;=&#8201;4) was homogenized in PBS and centrifuged to collect supernatants, 10&#8201;&#956;L supernatants were diluted serially and plated on LB agar for c.f.u. enumeration, and the other 10&#8201;&#956;L supernatants were applied for cytokine quantification (TNF-&#945;, IL-6, IL-&#946;, IL-10) with ELISA Kits.</p></sec><sec id="Sec35"><title>Antibacterial efficacy of C<italic toggle="yes">p</italic>E@BMV in a peritonitis model</title><p id="Par65">BALB/c mice were randomly allocated into six groups (<italic toggle="yes">n</italic>&#8201;=&#8201;5) and intraperitoneally injected with <italic toggle="yes">E. coli</italic> Xen14 solution (100&#8201;&#956;L, 1&#8201;&#215;&#8201;10<sup>8</sup> bacteria/mL) on day 0, 7, and 14. After 4&#8201;h of infection, the mice were intraperitoneally administered with different formulations using equivalent doses of Cip, Ea, and BMV were 1.76&#8201;mg/kg, 0.76&#8201;mg/kg, and 1.12&#8201;mg/kg, respectively, on days 0, 7, and 14. Bioluminescence of bacteria in the mouse peritoneal cavity was recorded at 0, 4, 8, and 24&#8201;h after the first treatment, using a bio-optical imaging system (IVIS&#174;, 45&#8201;s exposure time, medium binning, 1F/Stop, Open Emission Filter).</p><p id="Par66">On day 15, the blood of mice was collected from eyes (<italic toggle="yes">n</italic>&#8201;=&#8201;5) to measure the major blood parameters using (Mindray, Shenzhen, China), and the serum was further collected and applied for cytokine quantification (TNF-&#945;, IL-6, IL-&#946;, IL-10) with ELISA Kits. The mice were sacrificed on day 15. The peritoneal fluid of mice was collected and split for c.f.u. counting (<italic toggle="yes">n</italic>&#8201;=&#8201;4), and cytokine quantification (TNF-&#945;, IL-6, IL-&#946;, IL-10) with ELISA Kits, the spleen tissues were harvested and homogenized in PBS to obtain the supernatant for cytokine quantification with ELISA Kits. The major organs of mice (<italic toggle="yes">n</italic>&#8201;=&#8201;4) were homogenized in PBS and centrifuged to collect supernatants, 10&#8201;&#956;L supernatants were diluted serially and plated on LB agar for c.f.u. enumeration.</p></sec><sec id="Sec36"><title>Infiltrating immune cells analysis in vivo</title><p id="Par67">Immune cells in lung and spleen tissues at different time points (pneumonia model: days 3 and 7; peritonitis model: day 15) were analyzed by multiparameter flow cytometry following various treatments. The excised lung/spleen tissue was mechanically disrupted using the tip of a syringe, then 4&#8201;mL of digestion solution (Sigma, Germany) was added, and the mixture was put on a shaker (150&#8201;rpm) for 1&#8201;h to ensure complete digestion. Finally, the suspension was filtered through a 200-mesh sieve and centrifuged at 450&#8201;&#215;&#8201;<italic toggle="yes">g</italic> for 5&#8201;min to obtain a single-cell suspension. The single-cell suspension was subsequently stained with antibodies and analyzed using flow cytometry. Firstly, a single-cell suspension was incubated with anti-mouse CD16/32 (10&#8201;&#956;L, 0.5&#8201;mg/mL) at 4&#8201;&#176;C for 15&#8201;min to block Fc receptors. For macrophages, cells were stained with anti-mouse CD45-BV605 (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse CD11b-FITC (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse F4/80-BV421 (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse CD86-APC (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse CD206-PE (10&#8201;&#956;L, 0.2&#8201;mg/mL) for 30&#8201;min; For T cells, cells were stained with anti-mouse CD45-BV605 (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse CD3-FITC (10&#8201;&#956;L, 0.5&#8201;mg/mL), anti-mouse CD4-BV421 (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse CD8-APC (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse Foxp3-PE (10&#8201;&#956;L, 0.2&#8201;mg/mL) for 30&#8201;min; For B cells, cells were stained with anti-mouse CD45-BV605 (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse CD19-BV421 (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse CD138-APC (10&#8201;&#956;L, 0.2&#8201;mg/mL) for 30&#8201;min. Flow cytometry was performed by Beckman Coulter (CytoFlex, California, USA), and the result was analyzed using FlowJo software. Besides, the infection-draining lymph nodes (IDLN) were separated to collect immune cells, and the cells were stained with anti-mouse CD16/32 antibody (10&#8201;&#956;L, 0.5&#8201;mg/mL), anti-mouse CD45-BV605 (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse CD11c-BV421 (10&#8201;&#956;L, 0.2&#8201;mg/mL), anti-mouse CD86-APC (10&#8201;&#956;L, 0.2&#8201;mg/mL), and anti-mouse CD80-FITC (10&#8201;&#956;L, 0.2&#8201;mg/mL) for 30&#8201;min, and analyzed by Beckman Coulter.</p></sec><sec id="Sec37"><title>RNA sequencing</title><p id="Par68">Total RNA in lung tissue was extracted using TRIzol according to the user guide. Next, the purity and quantification of the collected RNA were measured by a NanoDrop 2000 spectrophotometer (Thermo Scientific, USA), and RNA integrity was checked by an Agilent 2100 Bioanalyzer (Agilent Technologies, USA). The transcriptome library was built using a VAHTS Universal V5 RNA-seq Library Prep Kit. The sequencing was conducted using an Illumina Novaseq 6000 sequencing platform. DESeq2 software was employed to analyze differentially expressed genes (DEG). The DEG was further investigated by GO and KEGG Pathway enrichment based on the hypergeometric distribution algorithm to identify the enriched GO and KEGG terms. RNA sequencing was conducted at the OE Biotech Co., Ltd. (Qingdao, China).</p></sec><sec id="Sec38"><title>2bRAD-M sequencing for microbiome</title><p id="Par69">The 2bRAD-M library construction was based on the method reported by Mikhail V Matz et al.<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. Genomic DNA of lung tissue was extracted using a MagPure Soil DNA KF Kit (MGBio, China), and the collected DNA (1&#8201;pg&#8211;200&#8201;ng) was further treated with the enzyme BcgI (4 U, NEB) for three hours. After ligating adapters to the DNA fragments by mixing 10&#8201;&#956;L digested DNA with a master mix (10&#8201;&#956;L, with 0.2&#8201;&#956;L adapters, and 800 U T4 DNA ligase) at 4&#8201;&#176;C overnight, the mixture was amplified using an 8% polyacrylamide gel, in which the bands around 100&#8201;bp were excised and DNA was collected. Sample-specific barcodes were incorporated via PCR using platform-compatible indexing primers, which were further purified by a QIAquick PCR purification kit. The 2BRAD-M sequencing was performed by the Illumina Nova PE150 platform.</p><p id="Par70">The databases of GTDB and Ensembl were applied to identify the species-level of 2bRAD-M markers. The set of 2bRAD tags derived from each genome was assigned under the corresponding GCF number, along with the taxonomic information associated with the whole genome. At the end, all single-copy 2bRAD tags (occurring once per genome) from each GCF were compared across all genomes to develop species-specific 2bRAD markers. The sequenced 2bRAD tags were mapped against the database to calculate relative abundance. The relative abundance of a specific species was determined by the proportion of microbial individuals in the species relative to the total number of detectable species in a sample.</p></sec><sec id="Sec39"><title>Statistical analysis</title><p id="Par71">All result data were presented as mean&#8201;&#177;&#8201;standard deviation (s.d.). Unless otherwise stated, all experiments used biological replication. Statistical analyses were analyzed using an unpaired Student&#8217;s <italic toggle="yes">t</italic>-test (two-tailed) for two groups, and one-way ANOVA with Tukey&#8217;s multiple comparisons was used for three or more groups. Significance levels were defined as follows: n.s., no significant difference, <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05; *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, and ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001; <italic toggle="yes">p</italic>-values were calculated by GraphPad Prism v8.3.0 (GraphPad Software) and marked on the figures.</p></sec><sec id="Sec40"><title>Reporting summary</title><p id="Par72">Further information on research design is available in the&#160;<xref rid="MOESM2" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p></sec></sec><sec id="Sec41" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41467_2025_60570_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41467_2025_60570_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41467_2025_60570_MOESM3_ESM.pdf" position="float" orientation="portrait"><caption><p>Description of Additional Supplementary Files</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41467_2025_60570_MOESM4_ESM.mp4" position="float" orientation="portrait"><caption><p>Supplementary Movie 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41467_2025_60570_MOESM5_ESM.mp4" position="float" orientation="portrait"><caption><p>Supplementary Movie 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41467_2025_60570_MOESM6_ESM.pdf" position="float" orientation="portrait"><caption><p>Transparent Peer Review file</p></caption></media></supplementary-material>
</p></sec><sec id="Sec42" sec-type="supplementary-material"><title>Source data</title><p>
<supplementary-material content-type="local-data" id="MOESM7" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41467_2025_60570_MOESM7_ESM.xlsx" position="float" orientation="portrait"><caption><p>Source Data</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Yuanfeng Li, Wei He, Yinzi Piao.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41467-025-60570-2.</p></sec><ack><title>Acknowledgements</title><p>This work was financially supported by the National Natural Science Foundation of China (Grant Nos. 52293383,&#160;52422307, 22475156, 52303181, 52203184, 22275043); the National Key Research and Development Program (2023YFB3809902); Zhejiang Provincial Natural Science Foundation Outstanding Youth Project (LR24H180001); Wenzhou Municipal Science and Technology Major Project (ZY2023031) and Scientific Research Project (Y20240113); and the Infectious Diseases X Discipline Cluster, the First Affiliated Hospital of Wenzhou Medical University.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Y. Li and Y. Liu conceived the project and strategies. L.S. and Y. Liu supervised the work and revised the manuscript. W.H., R.H., D.L. and Y. Li designed and conducted the experiments, analyzed the data and drafted the initial manuscript. Y.P. and Y.W. cultured the bacteria and conducted the biofilm-related experiments. M.P. carried out the TEM observations and H.L. performed the all-atom simulations. All authors reviewed and approved the final manuscript.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar1"><title>Peer review information</title><p id="Par73"><italic toggle="yes">Nature Communications</italic> thanks Jeremy Brown, Man-Wah Tan, and the other anonymous reviewer(s) for their contribution to the peer review of this work. A peer review file is available.</p></sec></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data generated in this study are provided in the paper, Supplementary Information, and Source Data file. The full image dataset is available from the corresponding author upon request. The data for 16s RNA sequencing and 2bRAD-M analysis used in this study are available in the Figshare database under accession DOI code 10.6084/m9.figshare.28792304.v1. Source data are provided in this paper.&#160;<xref ref-type="sec" rid="Sec42">Source data</xref> are provided with this paper.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par74">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>D</given-names></name><name name-style="western"><surname>Hussell</surname><given-names>T</given-names></name><name name-style="western"><surname>Dougan</surname><given-names>G</given-names></name></person-group><article-title>Chronic bacterial infections: living with unwanted guests</article-title><source>Nat. Immunol.</source><year>2002</year><volume>3</volume><fpage>1026</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1038/ni1102-1026</pub-id><pub-id pub-id-type="pmid">12407411</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Young, D., Hussell, T. &amp; Dougan, G. Chronic bacterial infections: living with unwanted guests. <italic toggle="yes">Nat. Immunol.</italic><bold>3</bold>, 1026&#8211;1032 (2002).<pub-id pub-id-type="pmid">12407411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni1102-1026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X</given-names></name><etal/></person-group><article-title>Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis</article-title><source>Nat. Nanotechnol.</source><year>2020</year><volume>15</volume><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/s41565-019-0600-1</pub-id><pub-id pub-id-type="pmid">31907443</pub-id><pub-id pub-id-type="pmcid">PMC7181370</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Hou, X. et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. <italic toggle="yes">Nat. Nanotechnol.</italic><bold>15</bold>, 41&#8211;46 (2020).<pub-id pub-id-type="pmid">31907443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-019-0600-1</pub-id><pub-id pub-id-type="pmcid">PMC7181370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Guiding antibiotics towards their target using bacteriophage proteins</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>5287</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-49603-4</pub-id><pub-id pub-id-type="pmid">38902231</pub-id><pub-id pub-id-type="pmcid">PMC11190222</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Zhao, X. et al. Guiding antibiotics towards their target using bacteriophage proteins. <italic toggle="yes">Nat. Commun.</italic><bold>15</bold>, 5287 (2024).<pub-id pub-id-type="pmid">38902231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-49603-4</pub-id><pub-id pub-id-type="pmcid">PMC11190222</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Zhu, J. et al. Multimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections. <italic toggle="yes">Nat. Nanotechnol</italic>. <bold>19</bold>, 1032&#8211;1043 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-024-01648-8</pub-id><pub-id pub-id-type="pmcid">PMC12126137</pub-id><pub-id pub-id-type="pmid">38632494</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolcott</surname><given-names>RD</given-names></name><name name-style="western"><surname>Ehrlich</surname><given-names>GD</given-names></name></person-group><article-title>Biofilms and chronic infections</article-title><source>JAMA</source><year>2008</year><volume>299</volume><fpage>2682</fpage><lpage>2684</lpage><pub-id pub-id-type="doi">10.1001/jama.299.22.2682</pub-id><pub-id pub-id-type="pmid">18544729</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wolcott, R. D. &amp; Ehrlich, G. D. Biofilms and chronic infections. <italic toggle="yes">JAMA</italic><bold>299</bold>, 2682&#8211;2684 (2008).<pub-id pub-id-type="pmid">18544729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.299.22.2682</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flemming</surname><given-names>H-C</given-names></name><etal/></person-group><article-title>Biofilms: an emergent form of bacterial life</article-title><source>Nat. Rev. Microbiol.</source><year>2016</year><volume>14</volume><fpage>563</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.94</pub-id><pub-id pub-id-type="pmid">27510863</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Flemming, H.-C. et al. Biofilms: an emergent form of bacterial life. <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>14</bold>, 563&#8211;575 (2016).<pub-id pub-id-type="pmid">27510863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro.2016.94</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sauer</surname><given-names>K</given-names></name><etal/></person-group><article-title>The biofilm life cycle: expanding the conceptual model of biofilm formation</article-title><source>Nat. Rev. Microbiol.</source><year>2022</year><volume>20</volume><fpage>608</fpage><pub-id pub-id-type="doi">10.1038/s41579-022-00767-0</pub-id><pub-id pub-id-type="pmid">35922483</pub-id><pub-id pub-id-type="pmcid">PMC9841534</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Sauer, K. et al. The biofilm life cycle: expanding the conceptual model of biofilm formation. <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>20</bold>, 608 (2022).<pub-id pub-id-type="pmid">35922483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-022-00767-0</pub-id><pub-id pub-id-type="pmcid">PMC9841534</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>D</given-names></name></person-group><article-title>Understanding biofilm resistance to antibacterial agents</article-title><source>Nat. Rev. Drug Discov.</source><year>2003</year><volume>2</volume><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1038/nrd1008</pub-id><pub-id pub-id-type="pmid">12563302</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Davies, D. Understanding biofilm resistance to antibacterial agents. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>2</bold>, 114&#8211;122 (2003).<pub-id pub-id-type="pmid">12563302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd1008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Tackling the emerging threat of antifungal resistance to human health</article-title><source>Nat. Rev. Microbiol.</source><year>2022</year><volume>20</volume><fpage>557</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00720-1</pub-id><pub-id pub-id-type="pmid">35352028</pub-id><pub-id pub-id-type="pmcid">PMC8962932</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Fisher, M. C. et al. Tackling the emerging threat of antifungal resistance to human health. <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>20</bold>, 557&#8211;571 (2022).<pub-id pub-id-type="pmid">35352028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-022-00720-1</pub-id><pub-id pub-id-type="pmcid">PMC8962932</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makabenta</surname><given-names>JMV</given-names></name><etal/></person-group><article-title>Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-0420-1</pub-id><pub-id pub-id-type="pmid">32814862</pub-id><pub-id pub-id-type="pmcid">PMC8559572</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Makabenta, J. M. V. et al. Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>19</bold>, 23&#8211;36 (2021).<pub-id pub-id-type="pmid">32814862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-020-0420-1</pub-id><pub-id pub-id-type="pmcid">PMC8559572</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control</article-title><source>Chem. Soc. Rev.</source><year>2019</year><volume>48</volume><fpage>428</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1039/C7CS00807D</pub-id><pub-id pub-id-type="pmid">30601473</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Liu, Y. et al. Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control. <italic toggle="yes">Chem. Soc. Rev.</italic><bold>48</bold>, 428&#8211;446 (2019).<pub-id pub-id-type="pmid">30601473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c7cs00807d</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amin Yavari</surname><given-names>S</given-names></name><name name-style="western"><surname>Castenmiller</surname><given-names>SM</given-names></name><name name-style="western"><surname>van Strijp</surname><given-names>JAG</given-names></name><name name-style="western"><surname>Croes</surname><given-names>M</given-names></name></person-group><article-title>Combating implant infections: shifting focus from bacteria to host</article-title><source>Adv. Mater.</source><year>2020</year><volume>32</volume><fpage>2002962</fpage><pub-id pub-id-type="doi">10.1002/adma.202002962</pub-id><pub-id pub-id-type="pmid">32914481</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Amin Yavari, S., Castenmiller, S. M., van Strijp, J. A. G. &amp; Croes, M. Combating implant infections: shifting focus from bacteria to host. <italic toggle="yes">Adv. Mater.</italic><bold>32</bold>, 2002962 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202002962</pub-id><pub-id pub-id-type="pmid">32914481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perciani</surname><given-names>CT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>LY</given-names></name><name name-style="western"><surname>Wood</surname><given-names>L</given-names></name><name name-style="western"><surname>MacParland</surname><given-names>SA</given-names></name></person-group><article-title>Enhancing immunity with nanomedicine: employing nanoparticles to harness the immune system</article-title><source>ACS Nano</source><year>2021</year><volume>15</volume><fpage>7</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c08913</pub-id><pub-id pub-id-type="pmid">33346646</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Perciani, C. T., Liu, L. Y., Wood, L. &amp; MacParland, S. A. Enhancing immunity with nanomedicine: employing nanoparticles to harness the immune system. <italic toggle="yes">ACS Nano</italic><bold>15</bold>, 7&#8211;20 (2021).<pub-id pub-id-type="pmid">33346646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c08913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immunomodulatory biomaterials against bacterial infections: progress, challenges, and future perspectives</article-title><source>Innovation</source><year>2023</year><volume>4</volume><fpage>100503</fpage><pub-id pub-id-type="pmid">37732016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xinn.2023.100503</pub-id><pub-id pub-id-type="pmcid">PMC10507240</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zhang, S. et al. Immunomodulatory biomaterials against bacterial infections: progress, challenges, and future perspectives. <italic toggle="yes">I</italic><italic toggle="yes">nnovation</italic><bold>4</bold>, 100503 (2023).<pub-id pub-id-type="pmid">37732016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xinn.2023.100503</pub-id><pub-id pub-id-type="pmcid">PMC10507240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arciola</surname><given-names>CR</given-names></name><name name-style="western"><surname>Campoccia</surname><given-names>D</given-names></name><name name-style="western"><surname>Montanaro</surname><given-names>L</given-names></name></person-group><article-title>Implant infections: adhesion, biofilm formation and immune evasion</article-title><source>Nat. Rev. Microbiol.</source><year>2018</year><volume>16</volume><fpage>397</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0019-y</pub-id><pub-id pub-id-type="pmid">29720707</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Arciola, C. R., Campoccia, D. &amp; Montanaro, L. Implant infections: adhesion, biofilm formation and immune evasion. <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>16</bold>, 397&#8211;409 (2018).<pub-id pub-id-type="pmid">29720707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-018-0019-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heim</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Lactate production by Staphylococcus aureus biofilm inhibits HDAC11 to reprogramme the host immune response during persistent infection</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>1271</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0756-3</pub-id><pub-id pub-id-type="pmid">32661313</pub-id><pub-id pub-id-type="pmcid">PMC7529909</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Heim, C. E. et al. Lactate production by Staphylococcus aureus biofilm inhibits HDAC11 to reprogramme the host immune response during persistent infection. <italic toggle="yes">Nat. Microbiol.</italic><bold>5</bold>, 1271&#8211;1284 (2020).<pub-id pub-id-type="pmid">32661313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-020-0756-3</pub-id><pub-id pub-id-type="pmcid">PMC7529909</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belkaid</surname><given-names>Y</given-names></name></person-group><article-title>Regulatory T cells and infection: a dangerous necessity</article-title><source>Nat. Rev. Immunol.</source><year>2007</year><volume>7</volume><fpage>875</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1038/nri2189</pub-id><pub-id pub-id-type="pmid">17948021</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Belkaid, Y. Regulatory T cells and infection: a dangerous necessity. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>7</bold>, 875&#8211;888 (2007).<pub-id pub-id-type="pmid">17948021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyers</surname><given-names>M</given-names></name><name name-style="western"><surname>Wright</surname><given-names>GD</given-names></name></person-group><article-title>Drug combinations: a strategy to extend the life of antibiotics in the 21st century</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>141</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0141-x</pub-id><pub-id pub-id-type="pmid">30683887</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Tyers, M. &amp; Wright, G. D. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>17</bold>, 141&#8211;155 (2019).<pub-id pub-id-type="pmid">30683887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-018-0141-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">N&#252;rnberger, T. &amp; Kemmerling, B. Pathogen-associated molecular patterns (PAMP) and PAMP-triggered immunity. In <italic toggle="yes">Annual Plant Reviews Volume 34: Molecular Aspects of Plant Disease Resistance</italic> 16&#8211;47 (2008).</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaparakis-Liaskos</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferrero</surname><given-names>RL</given-names></name></person-group><article-title>Immune modulation by bacterial outer membrane vesicles</article-title><source>Nat. Rev. Immunol.</source><year>2015</year><volume>15</volume><fpage>375</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1038/nri3837</pub-id><pub-id pub-id-type="pmid">25976515</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Kaparakis-Liaskos, M. &amp; Ferrero, R. L. Immune modulation by bacterial outer membrane vesicles. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>15</bold>, 375&#8211;387 (2015).<pub-id pub-id-type="pmid">25976515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Bacterial membrane vesicles: physiological roles, infection immunology, and applications</article-title><source>Adv. Sci.</source><year>2023</year><volume>10</volume><fpage>2301357</fpage><pub-id pub-id-type="doi">10.1002/advs.202301357</pub-id><pub-id pub-id-type="pmcid">PMC10477901</pub-id><pub-id pub-id-type="pmid">37357142</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Gan, Y. et al. Bacterial membrane vesicles: physiological roles, infection immunology, and applications. <italic toggle="yes">Adv. Sci.</italic><bold>10</bold>, 2301357 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202301357</pub-id><pub-id pub-id-type="pmcid">PMC10477901</pub-id><pub-id pub-id-type="pmid">37357142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>K</given-names></name><etal/></person-group><article-title>Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>2041</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22308-8</pub-id><pub-id pub-id-type="pmid">33824314</pub-id><pub-id pub-id-type="pmcid">PMC8024398</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Cheng, K. et al. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology. <italic toggle="yes">Nat. Commun.</italic><bold>12</bold>, 2041 (2021).<pub-id pub-id-type="pmid">33824314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-22308-8</pub-id><pub-id pub-id-type="pmcid">PMC8024398</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Lipid prodrug nanoassemblies via dynamic covalent boronates</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>6601</fpage><lpage>6614</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c12233</pub-id><pub-id pub-id-type="pmid">36999933</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ding, Y. et al. Lipid prodrug nanoassemblies via dynamic covalent boronates. <italic toggle="yes">ACS Nano</italic><bold>17</bold>, 6601&#8211;6614 (2023).<pub-id pub-id-type="pmid">36999933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c12233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Antimicrobial hybrid amphiphile via dynamic covalent bonds enables bacterial biofilm dispersal and bacteria eradication</article-title><source>Adv. Funct. Mater.</source><year>2023</year><volume>33</volume><fpage>2214299</fpage><pub-id pub-id-type="doi">10.1002/adfm.202214299</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Zhan, Y. et al. Antimicrobial hybrid amphiphile via dynamic covalent bonds enables bacterial biofilm dispersal and bacteria eradication. <italic toggle="yes">Adv. Funct. Mater.</italic><bold>33</bold>, 2214299 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Dynamic covalent nano-networks comprising antibiotics and polyphenols orchestrate bacterial drug resistance reversal and inflammation alleviation</article-title><source>Bioact. Mater.</source><year>2023</year><volume>27</volume><fpage>288</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">37113688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2023.04.014</pub-id><pub-id pub-id-type="pmcid">PMC10126917</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Li, Y. et al. Dynamic covalent nano-networks comprising antibiotics and polyphenols orchestrate bacterial drug resistance reversal and inflammation alleviation. <italic toggle="yes">Bioact. Mater.</italic><bold>27</bold>, 288&#8211;302 (2023).<pub-id pub-id-type="pmid">37113688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2023.04.014</pub-id><pub-id pub-id-type="pmcid">PMC10126917</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Coating of a novel antimicrobial nanoparticle with a macrophage membrane for the selective entry into infected macrophages and killing of intracellular staphylococci</article-title><source>Adv. Funct. Mater.</source><year>2020</year><volume>30</volume><fpage>2004942</fpage><pub-id pub-id-type="doi">10.1002/adfm.202004942</pub-id><pub-id pub-id-type="pmid">34737689</pub-id><pub-id pub-id-type="pmcid">PMC8562776</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Li, Y. et al. Coating of a novel antimicrobial nanoparticle with a macrophage membrane for the selective entry into infected macrophages and killing of intracellular staphylococci. <italic toggle="yes">Adv. Funct. Mater.</italic><bold>30</bold>, 2004942 (2020).<pub-id pub-id-type="pmid">34737689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adfm.202004942</pub-id><pub-id pub-id-type="pmcid">PMC8562776</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Rutherford</surname><given-names>ST</given-names></name><name name-style="western"><surname>Silhavy</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Huang</surname><given-names>KC</given-names></name></person-group><article-title>Physical properties of the bacterial outer membrane</article-title><source>Nat. Rev. Microbiol.</source><year>2022</year><volume>20</volume><fpage>236</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00638-0</pub-id><pub-id pub-id-type="pmid">34732874</pub-id><pub-id pub-id-type="pmcid">PMC8934262</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Sun, J., Rutherford, S. T., Silhavy, T. J. &amp; Huang, K. C. Physical properties of the bacterial outer membrane. <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>20</bold>, 236&#8211;248 (2022).<pub-id pub-id-type="pmid">34732874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-021-00638-0</pub-id><pub-id pub-id-type="pmcid">PMC8934262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N</given-names></name><etal/></person-group><article-title>Bacterial extracellular vesicle: a non-negligible component in biofilm life cycle and challenges in biofilm treatments</article-title><source>Biofilm</source><year>2024</year><volume>8</volume><fpage>100216</fpage><pub-id pub-id-type="doi">10.1016/j.bioflm.2024.100216</pub-id><pub-id pub-id-type="pmid">39184814</pub-id><pub-id pub-id-type="pmcid">PMC11341940</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Chen, N. et al. Bacterial extracellular vesicle: a non-negligible component in biofilm life cycle and challenges in biofilm treatments. <italic toggle="yes">Biofilm</italic><bold>8</bold>, 100216 (2024).<pub-id pub-id-type="pmid">39184814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioflm.2024.100216</pub-id><pub-id pub-id-type="pmcid">PMC11341940</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piao</surname><given-names>Y-Z</given-names></name><etal/></person-group><article-title>GOx-encapsulated iron-phenolic networks power catalytic cascade to eradicate bacterial biofilms</article-title><source>J. Control. Release</source><year>2022</year><volume>352</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.10.013</pub-id><pub-id pub-id-type="pmid">36241091</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Piao, Y.-Z. et al. GOx-encapsulated iron-phenolic networks power catalytic cascade to eradicate bacterial biofilms. <italic toggle="yes">J. Control. Release</italic><bold>352</bold>, 1&#8211;14 (2022).<pub-id pub-id-type="pmid">36241091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.10.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><etal/></person-group><article-title>DUSP1 protects against ischemic acute kidney injury through stabilizing mtDNA via interaction with JNK</article-title><source>Cell Death Dis.</source><year>2023</year><volume>14</volume><fpage>724</fpage><pub-id pub-id-type="doi">10.1038/s41419-023-06247-4</pub-id><pub-id pub-id-type="pmid">37935658</pub-id><pub-id pub-id-type="pmcid">PMC10630453</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Shi, L. et al. DUSP1 protects against ischemic acute kidney injury through stabilizing mtDNA via interaction with JNK. <italic toggle="yes">Cell Death Dis.</italic><bold>14</bold>, 724 (2023).<pub-id pub-id-type="pmid">37935658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-06247-4</pub-id><pub-id pub-id-type="pmcid">PMC10630453</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>DR</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>TA</given-names></name></person-group><article-title>The role of Fas ligand in immune privilege</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2001</year><volume>2</volume><fpage>917</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1038/35103104</pub-id><pub-id pub-id-type="pmid">11733771</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Green, D. R. &amp; Ferguson, T. A. The role of Fas ligand in immune privilege. <italic toggle="yes">Nat. Rev. Mol. Cell Biol.</italic><bold>2</bold>, 917&#8211;924 (2001).<pub-id pub-id-type="pmid">11733771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35103104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Wnt/&#946;-catenin signalling: function, biological mechanisms, and therapeutic opportunities</article-title><source>Signal Transduct. Target. Ther.</source><year>2022</year><volume>7</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00762-6</pub-id><pub-id pub-id-type="pmid">34980884</pub-id><pub-id pub-id-type="pmcid">PMC8724284</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Liu, J. et al. Wnt/&#946;-catenin signalling: function, biological mechanisms, and therapeutic opportunities. <italic toggle="yes">Signal Transduct. Target. Ther.</italic><bold>7</bold>, 3 (2022).<pub-id pub-id-type="pmid">34980884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00762-6</pub-id><pub-id pub-id-type="pmcid">PMC8724284</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Loo</surname><given-names>G</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>MJM</given-names></name></person-group><article-title>Death by TNF: a road to inflammation</article-title><source>Nat. Rev. Immunol.</source><year>2023</year><volume>23</volume><fpage>289</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00792-3</pub-id><pub-id pub-id-type="pmid">36380021</pub-id><pub-id pub-id-type="pmcid">PMC9665039</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">van Loo, G. &amp; Bertrand, M. J. M. Death by TNF: a road to inflammation. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>23</bold>, 289&#8211;303 (2023).<pub-id pub-id-type="pmid">36380021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-022-00792-3</pub-id><pub-id pub-id-type="pmcid">PMC9665039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Serum amyloid protein A in inflammatory bowel disease: from bench to bedside</article-title><source>Cell Death Discov.</source><year>2023</year><volume>9</volume><fpage>154</fpage><pub-id pub-id-type="doi">10.1038/s41420-023-01455-5</pub-id><pub-id pub-id-type="pmid">37164984</pub-id><pub-id pub-id-type="pmcid">PMC10172326</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Chen, R. et al. Serum amyloid protein A in inflammatory bowel disease: from bench to bedside. <italic toggle="yes">Cell Death Discov.</italic><bold>9</bold>, 154 (2023).<pub-id pub-id-type="pmid">37164984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-023-01455-5</pub-id><pub-id pub-id-type="pmcid">PMC10172326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Boehm</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JC</given-names></name></person-group><article-title>p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases</article-title><source>Nat. Rev. Drug Discov.</source><year>2003</year><volume>2</volume><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1038/nrd1177</pub-id><pub-id pub-id-type="pmid">12951578</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Kumar, S., Boehm, J. &amp; Lee, J. C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>2</bold>, 717&#8211;726 (2003).<pub-id pub-id-type="pmid">12951578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd1177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivashkiv</surname><given-names>LB</given-names></name></person-group><article-title>IFN&#947;: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy</article-title><source>Nat. Rev. Immunol.</source><year>2018</year><volume>18</volume><fpage>545</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0029-z</pub-id><pub-id pub-id-type="pmid">29921905</pub-id><pub-id pub-id-type="pmcid">PMC6340644</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Ivashkiv, L. B. IFN&#947;: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>18</bold>, 545&#8211;558 (2018).<pub-id pub-id-type="pmid">29921905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-018-0029-z</pub-id><pub-id pub-id-type="pmcid">PMC6340644</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>RC</given-names></name><name name-style="western"><surname>Rehan</surname><given-names>VK</given-names></name><name name-style="western"><surname>Roman</surname><given-names>J</given-names></name><name name-style="western"><surname>Sime</surname><given-names>PJ</given-names></name></person-group><article-title>PPARs: regulators and translational targets in the lung</article-title><source>PPAR Res.</source><year>2012</year><volume>2012</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1155/2012/342924</pub-id><pub-id pub-id-type="pmcid">PMC3503434</pub-id><pub-id pub-id-type="pmid">23213318</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Reddy, R. C., Rehan, V. K., Roman, J. &amp; Sime, P. J. PPARs: regulators and translational targets in the lung. <italic toggle="yes">PPAR Res.</italic><bold>2012</bold>, 1&#8211;2 (2012).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2012/342924</pub-id><pub-id pub-id-type="pmcid">PMC3503434</pub-id><pub-id pub-id-type="pmid">23213318</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montaigne</surname><given-names>D</given-names></name><name name-style="western"><surname>Butruille</surname><given-names>L</given-names></name><name name-style="western"><surname>Staels</surname><given-names>B</given-names></name></person-group><article-title>PPAR control of metabolism and cardiovascular functions</article-title><source>Nat. Rev. Cardiol.</source><year>2021</year><volume>18</volume><fpage>809</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1038/s41569-021-00569-6</pub-id><pub-id pub-id-type="pmid">34127848</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Montaigne, D., Butruille, L. &amp; Staels, B. PPAR control of metabolism and cardiovascular functions. <italic toggle="yes">Nat. Rev. Cardiol.</italic><bold>18</bold>, 809&#8211;823 (2021).<pub-id pub-id-type="pmid">34127848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-021-00569-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;rez-Guti&#233;rrez</surname><given-names>L</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>N</given-names></name></person-group><article-title>Biology and therapeutic targeting of vascular endothelial growth factor A</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2023</year><volume>24</volume><fpage>816</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1038/s41580-023-00631-w</pub-id><pub-id pub-id-type="pmid">37491579</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">P&#233;rez-Guti&#233;rrez, L. &amp; Ferrara, N. Biology and therapeutic targeting of vascular endothelial growth factor A. <italic toggle="yes">Nat. Rev. Mol. Cell Biol.</italic><bold>24</bold>, 816&#8211;834 (2023).<pub-id pub-id-type="pmid">37491579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-023-00631-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zelenitsky</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ariano</surname><given-names>RE</given-names></name><name name-style="western"><surname>Iacovides</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Harding</surname><given-names>GKM</given-names></name></person-group><article-title>AUC0&#8211;t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model</article-title><source>J. Antimicrob. Chemother.</source><year>2003</year><volume>51</volume><fpage>905</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1093/jac/dkg152</pub-id><pub-id pub-id-type="pmid">12654762</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Zelenitsky, S. A., Ariano, R. E., Iacovides, H., Sun, S. &amp; Harding, G. K. M. AUC0&#8211;t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. <italic toggle="yes">J. Antimicrob. Chemother.</italic><bold>51</bold>, 905&#8211;911 (2003).<pub-id pub-id-type="pmid">12654762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkg152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pickerill</surname><given-names>KE</given-names></name><name name-style="western"><surname>Paladino</surname><given-names>JA</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>JJ</given-names></name></person-group><article-title>Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>2000</year><volume>20</volume><fpage>417</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1592/phco.20.5.417.35062</pub-id><pub-id pub-id-type="pmid">10772373</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Pickerill, K. E., Paladino, J. A. &amp; Schentag, J. J. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. <italic toggle="yes">Pharmacother. J. Hum. Pharmacol. Drug Ther.</italic><bold>20</bold>, 417&#8211;428 (2000).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1592/phco.20.5.417.35062</pub-id><pub-id pub-id-type="pmid">10772373</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craig</surname><given-names>WA</given-names></name></person-group><article-title>Does the dose matter?</article-title><source>Clin. Infect. Dis.</source><year>2001</year><volume>33</volume><fpage>S233</fpage><lpage>S237</lpage><pub-id pub-id-type="doi">10.1086/321854</pub-id><pub-id pub-id-type="pmid">11524724</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Craig, W. A. Does the dose matter?. <italic toggle="yes">Clin. Infect. Dis.</italic><bold>33</bold>, S233&#8211;S237 (2001).<pub-id pub-id-type="pmid">11524724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/321854</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery</article-title><source>J. Am. Chem. Soc.</source><year>2013</year><volume>135</volume><fpage>17617</fpage><lpage>17629</lpage><pub-id pub-id-type="doi">10.1021/ja409686x</pub-id><pub-id pub-id-type="pmid">24160840</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Hu, X. et al. Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery. <italic toggle="yes">J. Am. Chem. Soc.</italic><bold>135</bold>, 17617&#8211;17629 (2013).<pub-id pub-id-type="pmid">24160840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja409686x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Couvreur</surname><given-names>P</given-names></name><name name-style="western"><surname>Lepetre-Mouelhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Garbayo</surname><given-names>E</given-names></name><name name-style="western"><surname>Blanco-Prieto</surname><given-names>MJ</given-names></name></person-group><article-title>Self-assembled lipid&#8211;prodrug nanoparticles</article-title><source>Nat. Rev. Bioeng.</source><year>2023</year><volume>1</volume><fpage>749</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1038/s44222-023-00082-0</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Couvreur, P., Lepetre-Mouelhi, S., Garbayo, E. &amp; Blanco-Prieto, M. J. Self-assembled lipid&#8211;prodrug nanoparticles. <italic toggle="yes">Nat. Rev. Bioeng.</italic><bold>1</bold>, 749&#8211;768 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Reaction-induced self-assembly of polymyxin mitigates cytotoxicity and reverses drug resistance</article-title><source>Adv. Mater.</source><year>2024</year><volume>36</volume><fpage>2406156</fpage><pub-id pub-id-type="doi">10.1002/adma.202406156</pub-id><pub-id pub-id-type="pmid">39022883</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Hu, X. et al. Reaction-induced self-assembly of polymyxin mitigates cytotoxicity and reverses drug resistance. <italic toggle="yes">Adv. Mater.</italic><bold>36</bold>, 2406156 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202406156</pub-id><pub-id pub-id-type="pmid">39022883</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Microenvironment-adaptive metallo-polymeric nanodecoys via subcomponent coordination for bacterial biofilm eradication and immunomodulation</article-title><source>Adv. Funct. Mater.</source><year>2024</year><volume>34</volume><fpage>2405487</fpage><pub-id pub-id-type="doi">10.1002/adfm.202405487</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Li, Y. et al. Microenvironment-adaptive metallo-polymeric nanodecoys via subcomponent coordination for bacterial biofilm eradication and immunomodulation. <italic toggle="yes">Adv. Funct. Mater.</italic><bold>34</bold>, 2405487 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Two-tailed dynamic covalent amphiphile combats bacterial biofilms</article-title><source>Adv. Mater.</source><year>2023</year><volume>35</volume><fpage>2301623</fpage><pub-id pub-id-type="doi">10.1002/adma.202301623</pub-id><pub-id pub-id-type="pmid">37207289</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Hu, X. et al. Two-tailed dynamic covalent amphiphile combats bacterial biofilms. <italic toggle="yes">Adv. Mater.</italic><bold>35</bold>, 2301623 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202301623</pub-id><pub-id pub-id-type="pmid">37207289</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Dynamic covalent prodrug nanonetworks via reaction-induced self-assembly for periodontitis treatment</article-title><source>ACS Nano</source><year>2024</year><volume>18</volume><fpage>34884</fpage><lpage>34901</lpage><pub-id pub-id-type="doi">10.1021/acsnano.4c12580</pub-id><pub-id pub-id-type="pmid">39663546</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Wu, H. et al. Dynamic covalent prodrug nanonetworks via reaction-induced self-assembly for periodontitis treatment. <italic toggle="yes">ACS Nano</italic><bold>18</bold>, 34884&#8211;34901 (2024).<pub-id pub-id-type="pmid">39663546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.4c12580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baym</surname><given-names>M</given-names></name><name name-style="western"><surname>Stone</surname><given-names>LK</given-names></name><name name-style="western"><surname>Kishony</surname><given-names>R</given-names></name></person-group><article-title>Multidrug evolutionary strategies to reverse antibiotic resistance</article-title><source>Science</source><year>2016</year><volume>351</volume><fpage>aad3292</fpage><pub-id pub-id-type="doi">10.1126/science.aad3292</pub-id><pub-id pub-id-type="pmid">26722002</pub-id><pub-id pub-id-type="pmcid">PMC5496981</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Baym, M., Stone, L. K. &amp; Kishony, R. Multidrug evolutionary strategies to reverse antibiotic resistance. <italic toggle="yes">Science</italic><bold>351</bold>, aad3292 (2016).<pub-id pub-id-type="pmid">26722002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad3292</pub-id><pub-id pub-id-type="pmcid">PMC5496981</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>BD</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>AE</given-names></name></person-group><article-title>Therapeutic strategies to combat antibiotic resistance</article-title><source>Adv. Drug Deliv. Rev.</source><year>2014</year><volume>78</volume><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2014.10.027</pub-id><pub-id pub-id-type="pmid">25450262</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Brooks, B. D. &amp; Brooks, A. E. Therapeutic strategies to combat antibiotic resistance. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>78</bold>, 14&#8211;27 (2014).<pub-id pub-id-type="pmid">25450262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2014.10.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J</given-names></name></person-group><article-title>Inhibiting quorum sensing by active targeted pH-sensitive nanoparticles for enhanced antibiotic therapy of biofilm-associated bacterial infections</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>10019</fpage><lpage>10032</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c12151</pub-id><pub-id pub-id-type="pmid">37234036</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Chen, Y., Gao, Y., Huang, Y., Jin, Q. &amp; Ji, J. Inhibiting quorum sensing by active targeted pH-sensitive nanoparticles for enhanced antibiotic therapy of biofilm-associated bacterial infections. <italic toggle="yes">ACS Nano</italic><bold>17</bold>, 10019&#8211;10032 (2023).<pub-id pub-id-type="pmid">37234036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c12151</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toyofuku</surname><given-names>M</given-names></name><name name-style="western"><surname>Schild</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaparakis-Liaskos</surname><given-names>M</given-names></name><name name-style="western"><surname>Eberl</surname><given-names>L</given-names></name></person-group><article-title>Composition and functions of bacterial membrane vesicles</article-title><source>Nat. Rev. Microbiol.</source><year>2023</year><volume>21</volume><fpage>415</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/s41579-023-00875-5</pub-id><pub-id pub-id-type="pmid">36932221</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Toyofuku, M., Schild, S., Kaparakis-Liaskos, M. &amp; Eberl, L. Composition and functions of bacterial membrane vesicles. <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>21</bold>, 415&#8211;430 (2023).<pub-id pub-id-type="pmid">36932221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-023-00875-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toyofuku</surname><given-names>M</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>N</given-names></name><name name-style="western"><surname>Eberl</surname><given-names>L</given-names></name></person-group><article-title>Types and origins of bacterial membrane vesicles</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0112-2</pub-id><pub-id pub-id-type="pmid">30397270</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Toyofuku, M., Nomura, N. &amp; Eberl, L. Types and origins of bacterial membrane vesicles. <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>17</bold>, 13&#8211;24 (2019).<pub-id pub-id-type="pmid">30397270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-018-0112-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><etal/></person-group><article-title>Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity</article-title><source>Nat. Nanotechnol.</source><year>2024</year><volume>19</volume><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1038/s41565-023-01553-6</pub-id><pub-id pub-id-type="pmid">38052943</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Liu, G. et al. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity. <italic toggle="yes">Nat. Nanotechnol.</italic><bold>19</bold>, 387&#8211;398 (2024).<pub-id pub-id-type="pmid">38052943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-023-01553-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Inorganic nanosheets facilitate humoral immunity against medical implant infections by modulating immune co-stimulatory pathways</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>4866</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-32405-x</pub-id><pub-id pub-id-type="pmid">35982036</pub-id><pub-id pub-id-type="pmcid">PMC9388665</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Yang, C. et al. Inorganic nanosheets facilitate humoral immunity against medical implant infections by modulating immune co-stimulatory pathways. <italic toggle="yes">Nat. Commun.</italic><bold>13</bold>, 4866 (2022).<pub-id pub-id-type="pmid">35982036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-32405-x</pub-id><pub-id pub-id-type="pmcid">PMC9388665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weyant</surname><given-names>KB</given-names></name><etal/></person-group><article-title>A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>464</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-36101-2</pub-id><pub-id pub-id-type="pmid">36709333</pub-id><pub-id pub-id-type="pmcid">PMC9883832</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Weyant, K. B. et al. A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens. <italic toggle="yes">Nat. Commun.</italic><bold>14</bold>, 464 (2023).<pub-id pub-id-type="pmid">36709333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-36101-2</pub-id><pub-id pub-id-type="pmcid">PMC9883832</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>R</given-names></name><etal/></person-group><article-title>High-yield, magnetic harvesting of extracellular outer-membrane vesicles from Escherichia coli</article-title><source>Small</source><year>2022</year><volume>18</volume><fpage>2204350</fpage><pub-id pub-id-type="doi">10.1002/smll.202204350</pub-id><pub-id pub-id-type="pmid">36269872</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Shi, R. et al. High-yield, magnetic harvesting of extracellular outer-membrane vesicles from Escherichia coli. <italic toggle="yes">Small</italic><bold>18</bold>, 2204350 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202204350</pub-id><pub-id pub-id-type="pmid">36269872</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritz</surname><given-names>JH</given-names></name><name name-style="western"><surname>Le Bourhis</surname><given-names>L</given-names></name><name name-style="western"><surname>Magalhaes</surname><given-names>JG</given-names></name><name name-style="western"><surname>Philpott</surname><given-names>DJ</given-names></name></person-group><article-title>Innate immune recognition at the epithelial barrier drives adaptive immunity: APCs take the back seat</article-title><source>Trends Immunol.</source><year>2008</year><volume>29</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.it.2007.10.002</pub-id><pub-id pub-id-type="pmid">18054284</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Fritz, J. H., Le Bourhis, L., Magalhaes, J. G. &amp; Philpott, D. J. Innate immune recognition at the epithelial barrier drives adaptive immunity: APCs take the back seat. <italic toggle="yes">Trends Immunol.</italic><bold>29</bold>, 41&#8211;49 (2008).<pub-id pub-id-type="pmid">18054284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.it.2007.10.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkin</surname><given-names>J</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>B</given-names></name></person-group><article-title>An overview of the immune system</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1777</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04904-7</pub-id><pub-id pub-id-type="pmid">11403834</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Parkin, J. &amp; Cohen, B. An overview of the immune system. <italic toggle="yes">Lancet</italic><bold>357</bold>, 1777&#8211;1789 (2001).<pub-id pub-id-type="pmid">11403834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(00)04904-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batista</surname><given-names>FD</given-names></name><name name-style="western"><surname>Harwood</surname><given-names>NE</given-names></name></person-group><article-title>The who, how and where of antigen presentation to B cells</article-title><source>Nat. Rev. Immunol.</source><year>2009</year><volume>9</volume><fpage>15</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1038/nri2454</pub-id><pub-id pub-id-type="pmid">19079135</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Batista, F. D. &amp; Harwood, N. E. The who, how and where of antigen presentation to B cells. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>9</bold>, 15&#8211;27 (2009).<pub-id pub-id-type="pmid">19079135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strugnell</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wijburg</surname><given-names>OLC</given-names></name></person-group><article-title>The role of secretory antibodies in infection immunity</article-title><source>Nat. Rev. Microbiol.</source><year>2010</year><volume>8</volume><fpage>656</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2384</pub-id><pub-id pub-id-type="pmid">20694027</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Strugnell, R. A. &amp; Wijburg, O. L. C. The role of secretory antibodies in infection immunity. <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>8</bold>, 656&#8211;667 (2010).<pub-id pub-id-type="pmid">20694027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro2384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pneumonia</article-title><source>Nat. Rev. Dis. Prim.</source><year>2021</year><volume>7</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1038/s41572-021-00259-0</pub-id><pub-id pub-id-type="pmid">33833230</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Torres, A. et al. Pneumonia. <italic toggle="yes">Nat. Rev. Dis. Prim.</italic><bold>7</bold>, 25 (2021).<pub-id pub-id-type="pmid">33833230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-021-00259-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Wu, F. et al. Single-atom Cu anchored on carbon nitride as a bifunctional glucose oxidase and peroxidase nanozyme for antibacterial therapy. <italic toggle="yes">ACS Nano</italic><bold>19</bold>, 10816&#8211;10828 (2025).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.4c12348</pub-id><pub-id pub-id-type="pmcid">PMC11948616</pub-id><pub-id pub-id-type="pmid">40087138</pub-id></mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piao</surname><given-names>Y-Z</given-names></name><etal/></person-group><article-title>One-component lipidic bicontinuous nanospheres as a smart drug loading platform to eradicate candida biofilms in oral and vaginal infection</article-title><source>Nano Today</source><year>2024</year><volume>54</volume><fpage>102123</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2023.102123</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Piao, Y.-Z. et al. One-component lipidic bicontinuous nanospheres as a smart drug loading platform to eradicate candida biofilms in oral and vaginal infection. <italic toggle="yes">Nano Today</italic><bold>54</bold>, 102123 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malde</surname><given-names>AK</given-names></name><etal/></person-group><article-title>An automated force field topology builder (ATB) and repository: version 1.0</article-title><source>J. Chem. Theory Comput.</source><year>2011</year><volume>7</volume><fpage>4026</fpage><lpage>4037</lpage><pub-id pub-id-type="doi">10.1021/ct200196m</pub-id><pub-id pub-id-type="pmid">26598349</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Malde, A. K. et al. An automated force field topology builder (ATB) and repository: version 1.0. <italic toggle="yes">J. Chem. Theory Comput.</italic><bold>7</bold>, 4026&#8211;4037 (2011).<pub-id pub-id-type="pmid">26598349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ct200196m</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>EL</given-names></name><etal/></person-group><article-title>CHARMM-GUI membrane builder toward realistic biological membrane simulations</article-title><source>J. Comput. Chem.</source><year>2014</year><volume>35</volume><fpage>1997</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1002/jcc.23702</pub-id><pub-id pub-id-type="pmid">25130509</pub-id><pub-id pub-id-type="pmcid">PMC4165794</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Wu, E. L. et al. CHARMM-GUI membrane builder toward realistic biological membrane simulations. <italic toggle="yes">J. Comput. Chem.</italic><bold>35</bold>, 1997&#8211;2004 (2014).<pub-id pub-id-type="pmid">25130509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcc.23702</pub-id><pub-id pub-id-type="pmcid">PMC4165794</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Microwave assisted antibacterial action of Garcinia nanoparticles on Gram-negative bacteria</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>2461</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-30125-w</pub-id><pub-id pub-id-type="pmid">35513402</pub-id><pub-id pub-id-type="pmcid">PMC9072325</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Qiao, Y. et al. Microwave assisted antibacterial action of Garcinia nanoparticles on Gram-negative bacteria. <italic toggle="yes">Nat. Commun.</italic><bold>13</bold>, 2461 (2022).<pub-id pub-id-type="pmid">35513402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-30125-w</pub-id><pub-id pub-id-type="pmcid">PMC9072325</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers</article-title><source>SoftwareX</source><year>2015</year><volume>1</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.softx.2015.06.001</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Abraham, M. J. et al. Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. <italic toggle="yes">SoftwareX</italic><bold>1</bold>, 19&#8211;25 (2015).</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humphrey</surname><given-names>W</given-names></name><name name-style="western"><surname>Dalke</surname><given-names>A</given-names></name><name name-style="western"><surname>Schulten</surname><given-names>K</given-names></name></person-group><article-title>VMD: visual molecular dynamics</article-title><source>J. Mol. Graph.</source><year>1996</year><volume>14</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id><pub-id pub-id-type="pmid">8744570</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Humphrey, W., Dalke, A. &amp; Schulten, K. VMD: visual molecular dynamics. <italic toggle="yes">J. Mol. Graph.</italic><bold>14</bold>, 33&#8211;38 (1996).<pub-id pub-id-type="pmid">8744570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0263-7855(96)00018-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahlgren</surname><given-names>C</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>A</given-names></name></person-group><article-title>Respiratory burst in human neutrophils</article-title><source>J. Immunol. Methods</source><year>1999</year><volume>232</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/S0022-1759(99)00146-5</pub-id><pub-id pub-id-type="pmid">10618505</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Dahlgren, C. &amp; Karlsson, A. Respiratory burst in human neutrophils. <italic toggle="yes">J. Immunol. Methods</italic><bold>232</bold>, 3&#8211;14 (1999).<pub-id pub-id-type="pmid">10618505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-1759(99)00146-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Surface-adaptive, antimicrobially loaded, micellar nanocarriers with enhanced penetration and killing efficiency in staphylococcal biofilms</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><fpage>4779</fpage><lpage>4789</lpage><pub-id pub-id-type="doi">10.1021/acsnano.6b01370</pub-id><pub-id pub-id-type="pmid">26998731</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Liu, Y. et al. Surface-adaptive, antimicrobially loaded, micellar nanocarriers with enhanced penetration and killing efficiency in staphylococcal biofilms. <italic toggle="yes">ACS Nano</italic><bold>10</bold>, 4779&#8211;4789 (2016).<pub-id pub-id-type="pmid">26998731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.6b01370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Eradication of multidrug-resistant staphylococcal infections by light-activatable micellar nanocarriers in a murine model</article-title><source>Adv. Funct. Mater.</source><year>2017</year><volume>27</volume><fpage>1701974</fpage><pub-id pub-id-type="doi">10.1002/adfm.201701974</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Liu, Y. et al. Eradication of multidrug-resistant staphylococcal infections by light-activatable micellar nanocarriers in a murine model. <italic toggle="yes">Adv. Funct. Mater.</italic><bold>27</bold>, 1701974 (2017).</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>E</given-names></name><name name-style="western"><surname>McKay</surname><given-names>JK</given-names></name><name name-style="western"><surname>Matz</surname><given-names>MV</given-names></name></person-group><article-title>2b-RAD: a simple and flexible method for genome-wide genotyping</article-title><source>Nat. Methods</source><year>2012</year><volume>9</volume><fpage>808</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2023</pub-id><pub-id pub-id-type="pmid">22609625</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Wang, S., Meyer, E., McKay, J. K. &amp; Matz, M. V. 2b-RAD: a simple and flexible method for genome-wide genotyping. <italic toggle="yes">Nat. Methods</italic><bold>9</bold>, 808&#8211;810 (2012).<pub-id pub-id-type="pmid">22609625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.2023</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>